US20080033366A1 - Compressible intravascular embolization particles and related methods and delivery systems - Google Patents

Compressible intravascular embolization particles and related methods and delivery systems Download PDF

Info

Publication number
US20080033366A1
US20080033366A1 US11/669,119 US66911907A US2008033366A1 US 20080033366 A1 US20080033366 A1 US 20080033366A1 US 66911907 A US66911907 A US 66911907A US 2008033366 A1 US2008033366 A1 US 2008033366A1
Authority
US
United States
Prior art keywords
particle
embolization
catheter
diameter
syringe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/669,119
Inventor
Louis Matson
Gerald McNamara
Donald Brandom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RJ MEDICAL Inc
Biosphere Medical Inc
Surgica Corp
Original Assignee
Surgica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surgica Corp filed Critical Surgica Corp
Priority to US11/669,119 priority Critical patent/US20080033366A1/en
Publication of US20080033366A1 publication Critical patent/US20080033366A1/en
Assigned to RJ MEDICAL, INC. reassignment RJ MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SURGICA CORPORATION
Assigned to SURGICA CORPORATION reassignment SURGICA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRANDOM, DONALD K., MCNAMARA, GERALD P., MATSON, LOUIS R.
Assigned to BIOSPHERE MEDICAL, INC. reassignment BIOSPHERE MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RJ MEDICAL, INC.
Assigned to RJ MEDICAL, INC. reassignment RJ MEDICAL, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 12/19/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0845. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF U.S. SERIAL NO. 11/669,119 TO ASSIGNEE RJ MEDICAL, INC. EFFECTIVE AS OF 12/19/2007. Assignors: SURGICA CORPORATION
Assigned to SURGICA CORPORATION reassignment SURGICA CORPORATION CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 01/30/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0829. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF U.S. SERIAL NO. 11/669,119 TO ASSIGNEE SURGICA CORPORATION NUNC PRO TUNC EFFECTIVE AS OF 01/30/2007. Assignors: BRANDOM, DONALD K., MCNAMARA, GERALD P., MATSON, LOUIS R.
Priority to US13/717,452 priority patent/US10448955B2/en
Assigned to WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT reassignment WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT PATENT SECURITY AGREEMENT Assignors: BIOSPHERE MEDICAL, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0036Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/1219Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/36Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Definitions

  • the present invention relates to compressible embolization particles, including supplemental embolization particles, methods of making and using the particles, and delivery systems for delivery of the particles.
  • Some intravascular interventional procedures produce an artificial embolism in mammals that is useful in controlling internal bleeding, blocking the blood supply to tumors, or relieving pressure in a vessel wall near an aneurysm.
  • Known methods for producing an artificial embolism include use of (1) inflatable and detachable balloons, (2) coagulating substances, (3) later-curing polymeric substances, (4) occlusive wire coils, (5) embolization particles, and (6) supplemental occlusive embolic materials.
  • Disadvantages relating to the known methods include recanalization, perforation of blood vessels, inadvertent downstream embolization due to fragmentation or release of trapped particles, poor positioning control, instability, imprecise sizing, and shrinkage or movement of the embolic material.
  • PVA foam or sponge embolization particles were made by chopping or grinding polyvinyl alcohol (PVA) foam or sponge.
  • PVA foam or sponge embolization particles are irregularly shaped and generally contain a range of pore sizes that are produced during the manufacturing process by whipping air into the PVA solution prior to crosslinking. Disadvantages of these particles include their non-precise size (aspect ratios) and open edges on the particles that cause them to clump together and subsequently plug up delivery catheters.
  • Spherical particles minimize these disadvantages.
  • spherical particles can penetrate deeper into the vasculature than traditional particles due to the uniform shape of the particle.
  • Existing spherical embolics include Biocompatibles International plc's Bead BlockTM, Biosphere Medical, Inc.'s EmbosphereTM and Boston Scientific Corporation's Contour SETM.
  • the Bead BlockTM product is a PVA get and does not have macropores (that is, the pores are less than 1 micron in diameter).
  • EmbosphereTM is a get made of an acrylic co-polymer (trisacryl) and does not have macropores.
  • Contour SETM is made of PVA has an onion shape but has no surface macropores.
  • spherical embolization particles have several disadvantages.
  • the smooth surface of these particles may affect the stable integration of such particles within the occlusive mass comprising the particles, clotted blood and ultimately fibrous tissue.
  • the compression of such particles is only about 20-35% in one dimension thereby limiting the size of the embolization particle that can be used in a given catheter.
  • the invention includes compressible substantially spherical, porous embolization particles.
  • the interior porous extend to the particle surface to form an exterior layer having exterior pores.
  • the compressible embolization particle preferably has a diameter from about 1,000 to 10,000 microns or more in its hydrated, fully expanded state.
  • the particles can be compressed in one dimension to at least 50% of the diameter of the fully extended particle and in some cases can be compressed to 5% of the original diameter.
  • the compressible embolization particle is preferably radiopaque.
  • the compressible embolization particle is made of a crosslinked polyvinyl alcohol (“PVA”) polymer.
  • PVA polyvinyl alcohol
  • the embolization particle also has an annular porous ring around the spherical particle which is a generated during particle formation.
  • the invention also includes an artificial embolization kit.
  • the kit has one or more compressible embolization particle as described herein and a delivery device.
  • the delivery device has a connection component and two syringes.
  • the connection component is adapted to connect with the two syringes and to control the flow of fluid in the delivery device.
  • the invention includes an embolization device comprising a compressible embolization particle(s) and a delivery system such as a catheter.
  • the embolization device contains the particle in the lumen of the catheter.
  • the invention also includes a method of embolization where a percutaneous delivery system containing a compressible embolization particle is positioned so that the delivery system is in proximity to a target region of a blood vessel.
  • the particle is compressed in the lumen of the delivery system and has a cross-sectional diameter that corresponds to the diameter of the lumen
  • the compressed embolization particle is then ejected from the delivery system by pressure or the use of a blunt ended guidewire so that the particle is initially positioned in the target region.
  • the particle expands.
  • the diameter of the uncompressed hydrated embolization particle is preferably chosen so that after expansion, the particle attains an expanded state that creates pressure against the interior surface of the vascular wall.
  • the embolization particle therefore conforms to the cross section of the blood vessel.
  • the invention also includes a method of loading an embolization particle into a catheter.
  • an embolization particle is positioned in a luer hub of a catheter.
  • a syringe containing hydration fluid is coupled to the luer hub and operated to urge the embolization particle out of the luer hub and into the catheter.
  • the syringe is then removed.
  • the particle is then urged through the catheter and into a target area of a patient with a guidewire.
  • the invention in another embodiment, includes a method of loading an embolization particle into a catheter where an embolization particle is positioned in a luer hub of a catheter.
  • a stopcock is connected to the luer hub and first and second syringes are connected to the stopcock, at least one syringe initially containing hydration fluid.
  • the first syringe is operated to urge the embolization particle out of the luer hub and into the catheter.
  • the second syringe is operated to urge the particle through the catheter.
  • the invention includes a method of embolization.
  • at least one compressible embolization particle is urged through a catheter and positioned in a target region of a blood vessel.
  • the particle is in a compressed state while being urged through the catheter and expands to an expanded state upon exiting the catheter.
  • a first embolization device is positioned in a target region of a blood vessel.
  • a second embolization device is then positioned in the blood vessel in close proximity to the first embolization device.
  • At least one of the embolization devices is a compressible embolization particle as described herein.
  • the invention also includes a method of making a compressible embolization particle.
  • the method includes mixing a polymer, such as PVA, a crosslinking agent, a gas and optionally a porogen to form the foam.
  • the foam is then placed in a spherical mold having a diameter that corresponds to the desired diameter of the compressible embolization particle when hydrated for use. After curing, the particle is removed from the mold and the porogen is dissolved and separated from the particle to produce the embolization particle. In some situations, porogen is hydrolyzed in which case it is removed by rinsing.
  • FIG. 1 is a cross-sectional view of a spherical polyvinyl alcohol foam embolization particle, according to one embodiment of the present invention.
  • FIG. 2 is a cross-sectional view of a spherical polyvinyl alcohol foam embolization particle, according to another embodiment of the present invention.
  • FIGS. 3A, 3B and 3 C are Scanning Electron Micrographs (SEM's) of a dehydrated PVA particle made according to the invention.
  • FIG. 3A shows a substantially spherical porous particle at 80 ⁇ magnification having surface pores. Some interior pores can also be seen. An annular ring can be seen encircling the “equator” of the particle.
  • FIG. 3B is a close up (300 ⁇ magnification) of the surface of the north central hemisphere of the particles in FIG. 3A .
  • FIG. 3C depicts a cross section of a dehydrated PVA compressible particle at 80 ⁇ magnification.
  • FIG. 4 is a side view of a delivery system, according to one embodiment of the present invention.
  • FIG. 5 is a perspective view of a kit containing a delivery system and an embolization particle, according to one embodiment of the present invention.
  • FIG. 6 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with an embolization coil, according to one embodiment of the present invention.
  • FIG. 7 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with two embolization coils, according to one embodiment of the present invention.
  • FIG. 8 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with embolization particles, according to one embodiment of the present invention.
  • the compressible particles can be used for use in the creation of an artificial embolism that can be used to treat aneurysms, tumors, bleeding, vascular malformations, or otherwise be used to block blood flow to undesired areas by occluding blood vessels.
  • the device is a dry, dehydrated substantially spherical particle of biocompatible polyvinyl alcohol (“PVA”) foam material that when hydrated is compressible from its original hydrated volume to a constrained or smaller volume that can subsequently expand back toward the original volume.
  • PVA polyvinyl alcohol
  • compressibility is defined as the ratio of the amount of the diameter of the particle that has been compressed to the total diameter of the particle in its fully expanded state.
  • the particle can be compressed to a diameter perpendicular to the catheter lumen that is about 5% to about 90%, about 25% to about 85%, and about 40% to about 80% of the diameter of the expanded particle. This does not include the annular ring, if present.
  • the compressed particle is delivered to a target region of a blood vessel by an embolization device comprising a catheter and the compressible particle.
  • an embolization device comprising a catheter and the compressible particle.
  • the compressible particle Prior to the embolization procedure, the compressible particle is placed in the catheter lumen in a compressed state. After ejection from the lumen, the particle expands to provide for mechanical fixation of the particle within the vascular area, thereby providing occlusion of the vascular area.
  • FIG. 1 depicts an expandable embolization particle 10 , according to one embodiment of the present invention.
  • Particle 10 is preferably made of expandable PVA foam material and has a compressible, porous, spherical structure.
  • the expandable material is formalin crosslinked PVA foam.
  • the particle 10 can be made of polyurethane.
  • the particle 10 can have any shape with a circular profile configured to provide a sealed occlusion with respect to the blood vessel in which it is positioned.
  • the particle 10 according to one embodiment can be cylindrical.
  • the particle 10 has an interior or inner portion 12 and a exterior layer 14 (also referred to as an “exterior portion” or “skin”).
  • the interior portion 12 is more porous and contains pores with a larger diameter in comparison to the pores present in the skin 14 .
  • the pores in the exterior layer 14 have a diameter that is generally smaller than the diameter of the pores found the interior portion 12 .
  • the exterior layer 14 pores have a diameter that is generally smaller than the diameter of the pores found in the interior portion 12 of the particle.
  • the pores in the interior portion of the particle are “macropores” having diameters of 10, 25, 50, 100, 200, 300, 400 or 500 microns or more.
  • the skin 14 has fewer pores, fewer and smaller pores, or no pores in comparison to the interior portion.
  • Interconnected pores also referred to as “open pores” as used in the present application refers to pores that are in fluid communication within a solid material.
  • the interconnected pores define an open, interconnected architecture of volume elements within the particle that can contain liquid in the hydrated state or gas in a dehydrated state.
  • the particles of the present invention are substantially spherical.
  • substantially spherical refers to a generally spherical shape having a maximum diameter/minimum diameter ratio of from about 1.0 to about 2.0, more preferably from about 1.0 to about 1.5, and most preferably from about 1.0 to about 1.2. This definition is intended to include true spherical shapes and ellipsoidal shapes, along with any other shapes that are encompassed within the maximum diameter/minimum diameter ratio.
  • FIGS. 3A, 3B and 3 C are scanning electron micrographs (SEM's) of a dehydrated PVA particle made according to the invention.
  • FIG. 3A shows a substantially spherical porous particle at 80 ⁇ magnification having surface pores. Some interior pores can also be seen.
  • An annular ring can be seen encircling the “equator” of the particle.
  • the annular ring is an artifact formed during curing in the joint between the two halves of the mold used to make the particle.
  • the ring can be of any desired diameter by using a die to trim the ring before particle removal from one of the half molds.
  • the annular ring is believed to impart additional stability to embolisms formed from the particles.
  • FIG. 3B is a close up (300 ⁇ magnification) of the surface of the north central hemisphere of the particles in FIG. 3A .
  • Interior pores can be readily seen. Some of the surface pores have diameters as large as about 50 microns with some having diameters as large as 100 or more microns.
  • FIG. 3C depicts a cross section of a dehydrated PVA compressible particle at 80 ⁇ magnification. The interior has some pores having a diameter from 100 to 500 microns with many of the pores having a diameter less than about 100 micron. The minimum pore size is about 1 micron.
  • the exterior layer 14 in FIG. 1 is an outer skin that provides increased structural strength, thereby reducing risk of fragmentation. Further, the exterior layer 14 can provide reduced friction when the exterior layer 14 contacts objects such as the interior portions of delivery systems during use. Such a strong exterior layer 14 with reduced exterior friction can aid in insertion into a blood vessel and reduce risk of recannalization and further, unintended embolization caused by debris that may be trapped in the larger inner pores. In one aspect of the invention, the relatively fewer, smaller, or lack of pores in the skin 14 enhance the structural strength and friction reducing characteristics of the skin 14 .
  • the structural strength of the skin results in a particle exhibiting much greater compressive size reduction by allowing for an interior portion having larger, more compressible pores and a foam with memory, wherein “memory” refers to the capacity of the particle to recover toward its original shape after deformation (elastic recovery). That is, the particle has memory because it can be compressed to a smaller diameter and upon release of the compressive force will return toward its original non-compressed diameter.
  • porogen refers to a pore forming material dispersed in the polymer solution and subsequently removed to yield pores, voids, or free volume in the material.
  • the porogen is starch that can be solubilized after particle formation.
  • the porogen can be, but is not limited to, carbon dioxide, polyethylene glycol, or any of the inert gases.
  • crosslinking component can be formaldehyde and the catalyst can be hydrochloric acid.
  • the catalyst can be an acid such as sulfuric acid or, in a further alternative, almost any known mineral acid.
  • the crosslinking component and catalyst are added to the mixture, air or any other inert gas is then added or “whipped” into the mixture to create a foam.
  • the air is preferably added to the mixture using a high speed mixer.
  • a single element egg beater in a high speed air motor (7,000 ⁇ 400 rpm) can be used to make the foam before the mixture has cross linked to any significant degree.
  • the mixing continues until the mixture stops expanding.
  • the mixing period lasts for from about 5 seconds to about 4 minutes. In a further alternative, the mixing period lasts for from about 10 seconds to about 1 minute.
  • the reaction mixture of PVA, porogen, and air is placed into a mold and heated for about five hours.
  • the mixture is heated for a period of time ranging from about three hours to about ten hours.
  • the mixture is heated for a period of time ranging from about 4 hours to about 7 hours. It is understood that crosslinking begins to occur after the addition of the crosslinking component and the crosslinking catalyst such that the resulting product removed from the mold comprises crosslinked PVA.
  • the mold is a polypropylene mold defining a substantially spherical void, thereby producing a substantially spherical particle.
  • this definition is intended to include true spherical shapes and ellipsoidal shapes, along with any other shapes that are encompassed within the maximum diameter/minimum diameter ratio.
  • the compression or pressure placed upon the exterior portions of the mixture ensures that the entire void is filled with mixture and that the mixture contacts all or substantially all of the surface of the mold defining the void, thereby ensuring a smooth, skin or surface to the resulting particle that can contain pores or a relatively nonporous skin.
  • the polypropylene in the mold further enhances the smooth—even, in some cases, glossed—finish of the resulting particle.
  • the resulting particle consists of an interior portion having larger pores as a result of the relatively unconstrained, non-compressed formation in away from the surface of the mold and an exterior layer or skin that is compacted, relatively smooth, and finished as a result of the compression on those areas of the mixture caused by contact with the mold, though one or more macropores may be present in the skin.
  • the mold has two components, both of which define a hemispherical void.
  • the reaction mixture is injected into both voids in excess such that when the two molds are coupled to define a spherical void, the mixture is compressed or pressured in the void and the excess mixture is forced out of the bleed hole in communication with the void.
  • the result of the compression or pressure is a particle with a relatively nonporous or microporous skin or surface with a substantially smooth finish.
  • a particle or particles of the present invention can be positioned in a target region of a blood vessel to occlude the vessel.
  • the method includes delivery of the particle to the target region with a delivery system.
  • the user or physician can perform angiography to determine the vascular supply to the target area. Further, the resulting angiogram can be used to determine the appropriate route for delivery system insertion.
  • another pre-delivery step is hydration of the embolization particle.
  • the particle is hydrated by adding hydration fluid to the particle in a container—or placing the particle in an amount of hydration fluid in a container.
  • the particle may be compressed while it is in the fluid.
  • hydration fluid is drawn into the voids or pores in the interior portions of the particle, thereby accelerating hydration of the particle.
  • this hydration process can be performed in a period of about 5 seconds. Alternatively, the process can be performed in a period ranging from about 2 seconds to about 10 seconds.
  • the hydration fluid is any known fluid for hydrating embolization particles including contrast agent, saline, or any combination thereof, where it is understood that the term “saline” encompasses any salt solution acceptable for physiological use. It is understood that hydration fluid, may contain contrast agent or may be a contrast agent. For example, the hydration fluid can be a contrast agent such as Oxilan 300®.
  • Delivery of the particle includes positioning the delivery system such that the system is in fluid communication with the target area of the blood vessel.
  • the delivery system comprises a catheter.
  • the delivery process further includes placing a compressible embolization particle into a lumen of the delivery system.
  • the diameter of the particle in its expanded state is greater than the inner diameter of the lumen of the delivery system such that the particle is in a compressed state in the lumen.
  • the particle is then delivered to the target region by ejecting or expelling the particle from the lumen of the delivery system. Upon exit from the lumen into the target area, the particle expands from its compressed state toward its expanded state. As depicted in FIG. 2 , the particle 20 is configured such that the diameter of the target region of the blood vessel 22 is greater than the diameter of the lumen but less than the diameter of the particle 20 in its fully expanded state such that the particle 20 upon exiting the delivery system expands until the exterior 24 of the particle 20 contacts the inner wall 26 of the vessel 22 .
  • the diameter of the vessel 22 as described above results in the particle 20 being in a compressed state (though not as compressed as in the lumen of the delivery system), thus resulting in the particle 20 exerting a continuous outward pressure on the inner wall 26 of the blood vessel.
  • This pressured contact between the particle 20 and the blood vessel 22 can help to stabilize the particle 20 in a single position within the target area of the blood vessel 22 , thereby resulting in occlusion of the vessel 22 .
  • the pressured contact works to retain the particle 20 in the single position in the vessel 22 such that a substantial force is required to move the particle 20 .
  • the pressured contact results in the substantial mechanical fixation of the particle 20 in a single position in the blood vessel 22 .
  • additional mechanical fixation occurs as a result of the blood clotting caused by the presence of the particle and by the PVA material, and further occurs as a result of the subsequent healing process.
  • the blood clotting forms on both sides of the particle or at least downstream of the particle, thereby providing further mechanical fixation.
  • the immune system of the human body recognizes that the particle is a foreign object and attempts to form tissue around the particle, thereby providing further mechanical fixation.
  • the first step in delivering the particle of the present invention to the target region is positioning a catheter in a patient such that the distal end of the catheter is located at or near the target region in the patient's blood vessel.
  • the catheter has a stopcock at the proximal end of the catheter configured to close off the catheter to prevent loss of blood through the catheter prior to delivery of a particle of the present invention through the catheter.
  • a stopcock is placed on the proximal end of the catheter after the catheter is positioned in the patient to prevent blood loss through the catheter.
  • the embolization particle of the present invention is positioned in the connection portion of the catheter (not shown), which is located at the proximal end of the catheter.
  • the connection portion of the catheter is a luer connector hub such that the particle is positioned in the connector hub.
  • the connection portion of the catheter is the stopcock.
  • the particle of the present invention in one aspect of the invention, has a diameter that is smaller than the inner diameter of the connection portion of the catheter but larger than the inner diameter of the catheter lumen such that the particle is easily positioned in the hub but requires force to be urged into the catheter lumen.
  • the next step is to urge the particle from the luer connector hub into the catheter lumen.
  • the particle is urged into the catheter lumen using a syringe containing hydration fluid. That is, with the particle positioned in the connector hub of the catheter, a syringe is connected with the hub, thereby locking or enclosing the particle into the connection between the hub and the syringe. The plunger of the syringe is then depressed, providing a hydraulic force that moves the particle into the catheter lumen.
  • the particle is then urged along the catheter lumen and urged out of the catheter and into the target region using a blunt-ended guidewire.
  • the syringe used to load the particle into the lumen is removed from the catheter. It is possible to remove the syringe without blood loss through the catheter because the particle, having in its expanded state a larger diameter than the lumen of the catheter, has sealed the lumen of the catheter.
  • a guidewire is inserted into the proximal portion of the catheter and contacts the particle, urging it toward and ultimately out of the distal end of the catheter and into the target region of the patient's blood vessel.
  • FIG. 4 depicts a delivery system or device 30 , according to one embodiment of the present invention.
  • the device 30 has a connection component 32 which, in this embodiment, is a three-way stopcock.
  • the coupling portion 38 of the connection component 32 is coupled to a catheter (not shown).
  • Syringes 34 and 36 are coupled to the stopcock 32 .
  • FIG. 5 depicts an alternative embodiment in which the delivery system is provided as a kit 40 .
  • the kit 40 includes two syringes 42 and 44 , a connection component 46 , and a vial 48 containing at least one embolization particle.
  • the delivery system 30 can be used in the following manner, according to one embodiment of the present invention.
  • the embolization particle is positioned in the connection portion of the catheter.
  • the coupling portion 38 of the connection component 32 of the delivery device 30 is coupled to the luer connection hub of the catheter (not shown), thereby enclosing the embolization particle within the connection between the coupling portion 38 and the luer connection hub of the catheter (not shown).
  • one of the two syringes 34 or 36 contains hydration fluid and the other of the two syringes 34 or 36 is empty.
  • syringe 36 is a 1 ml syringe that contains hydration fluid, while syringe 34 is empty.
  • syringe 36 is empty and syringe 34 contains hydration fluid.
  • the stopcock 32 is then adjusted such that the syringe 34 is in fluid communication with only the catheter lumen.
  • the user injects the small amount of hydration fluid from the syringe 34 into the catheter, thereby loading the particle into the catheter lumen.
  • the user pushes the plunger of syringe 34 quickly and forcefully, thereby urging the particle into the lumen.
  • the step of transferring a small amount of hydration fluid to the syringe 34 and then forcefully injecting the small amount into the catheter, thereby loading the particle can be repeated once or twice to insure loading of the particle.
  • a syringe containing hydration fluid is used to urge the particle along the catheter.
  • the stopcock 32 can be adjusted such that syringe 36 containing hydration fluid is in fluid communication with the catheter lumen and syringe 36 can be used to urge the particle along the catheter.
  • the delivery device 30 is removed from the catheter and another, separate syringe containing hydration fluid is connected to the catheter and used to urge the particle through the catheter.
  • a guidewire is used to urge the particle through the catheter.
  • the present invention relates to a supplemental occlusion particle configured to enhance the treatment of aneurysms, tumors, bleeding, and otherwise completely block blood flow to undesired anatomical areas by supplementing the occlusion of blood vessels.
  • This embodiment of the invention relates to the introduction of a secondary, supplemental compressible embolic device into a target area of a blood vessel to compliment the action of one or more primary embolic devices or materials.
  • Such primary embolic devices can be smaller embolization particles such as MicrostatTM (Surgical Corporation); Contour SETM (Boston Scientific Corporation), EmbosphereTM (Biosphere Medical Inc.) or Bead BlockTM (Biocompatables International Plc), embolization coils, or liquid polymer embolization systems which cure in vivo.
  • embolization particles such as MicrostatTM (Surgical Corporation); Contour SETM (Boston Scientific Corporation), EmbosphereTM (Biosphere Medical Inc.) or Bead BlockTM (Biocompatables International Plc), embolization coils, or liquid polymer embolization systems which cure in vivo.
  • FIG. 6 depicts a supplemental occlusion particle 50 , according to an alternative embodiment of the present invention.
  • the particle 50 is positioned to operate in conjunction with the embolization coil 52 to provide occlusion of the blood vessel 54 .
  • the particle 50 is configured to expand from a compressed state having a first volume to an expanded state having a second, relatively larger volume in comparison with the first.
  • the particle 50 is configured to expand within the vessel 54 and thereby provide a degree of blood-flow-blocking mechanical fixation to support or enhance the embolic action of the primary device 52 .
  • the use of the supplemental particle 50 in cooperation with a primary embolization device such as the coil 52 results in complete or substantially complete occlusion and reduces or even eliminates the risk of recanalization.
  • the particle 50 is positioned to operate in conjunction with two embolization coils 52 and 56 to provide occlusion. As shown in yet another alternative embodiment in FIG. 8 , the particle 50 can also be used in conjunction with smaller embolization particles 58 or any other known embolization device.
  • the supplemental occlusion particle 50 in accordance with one aspect of the invention, is an embolic PVA particle as described above and depicted in FIG. 1 , having an inner, porous portion and an outer layer comprised of fewer and/or closed pores having an average diameter that is smaller than the average diameter of the pores in the inner portion of the particle
  • the supplemental occlusion particle 50 is any embolic device having materials with a highly compressible porous structure, such as crosslinked PVA foams.
  • the PVA foam can also be configured radiopaque by a variety of well known methods.
  • the supplemental occlusion particle can be any known embolic particle or device capable of expanding radially inside the vessel and thereby providing a degree of mechanical fixation to support the blocking action of the primary embolization device to provide complete and permanent occlusion of the vessel.
  • the supplemental particle can operate in the following manner.
  • the supplemental particle is positioned in operable proximity to the primary occlusion device. That is, the supplemental particle is positioned in a location such that it operates to enhance the degree of blood-flow blockage created by the primary device.
  • the supplemental particle is positioned using a delivery method or system. According to one embodiment, the particle is positioned using a guidewire as described herein. Alternatively, the particle is positioned using one of the systems depicted in FIG. 4 or 5 or a similar system.
  • the delivery system is positioned with respect to the target area of the blood vessel to allow for positioning the particle in the target area.
  • the particle is placed in the lumen of the delivery system which, according to one embodiment, is a catheter.
  • the lumen has a smaller inner diameter than the diameter of the particle in its expanded state. As such, the particle is retained in a compressed state by the lumen. The particle is then expelled or ejected from the lumen of the delivery device into the blood vessel at the target area such that it is positioned in operable proximity with the primary device. Upon or during exit from the lumen, the supplemental particle expands in the blood vessel.
  • Tables I-VI compare the compressibility and catheter compatibility of EmbosphereTM particles (Tables I and II), Contour SETTM particles (Tables III and IV) and MaxistatTM particles (which are within the scope of the invention) (Tables V and VI).
  • a crosslinked PVA embolization particle was prepared in the following manner. A mixture of 26.2 grams of PVA and 98.9 grams of deionized water was rapidly heated to 100° C. and held for 12 minutes. Subsequently, 39.9 grams of the resulting PVA solution was transferred for reaction purposes into a reaction kettle (a glass beaker) and set aside and allowed to cool. Separately, a mixture of 15 grams of rice starch and 135 grams of deionized water was heated to 80° C. and then 9.5 grams of the material was added to the PVA solution and thoroughly mixed. To this resulting mixture was added 3.6 grams of concentrated hydrochloric acid and 6.4 grams of about 37% formaldehyde (formalin solution) to form the reaction solution.
  • reaction solution was then placed in a 2 liter glass reaction kettle and mixed at about 7000 rpm with a high-speed mixer having a high-speed air motor and using a mixing blade to whip air into the mixture until the foam stopped expanding and the resulting mixture achieved an appearance similar to whipped cream, which required about 30 seconds of mixing.
  • the mixing blade was similar in configuration to an egg beater.
  • the reaction mixture was transferred to spherical molds of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm diameter and allowed to cure for 5 hours at 55° C.
  • the polypropylene molds used in this example have two identical 1 inch by 1 inch square pieces that are 0.2 inches in thickness. Each piece defines a hemisphere on one side, wherein the hemisphere is sized according to the desired size of the embolization particle. Further, each piece also defines a 0.039 inch bleed hole in fluid communication with the hemisphere, thereby allowing relief of any overfill amount through the bleed hole.
  • the resulting products were partially acetalized crosslinked PVA sponges, which were then thoroughly washed to remove excess formaldehyde and hydrochloric acid. Certain portions of the resulting sponges were then removed, including the center ring and the poles (flashing), to create substantially spherical particles of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm in diameter in their hydrated, fully expanded state. The sponges were then dried for 16.5 hours at 50° C. to complete the manufacturing process.
  • Example 2 The same procedure performed in Example 1 was repeated, but the formaldehyde additive was reduced to 5.2 grams. It was believed that the reduction in formaldehyde would change the pot-life of the reaction solution, wherein “pot-life” is intended to mean the useful life of the mixture (after some period of time, the mixture ages to the point that it cannot be used to create a particle of the present invention). However, no significant change in pot-life was observed.
  • Example 2 The same procedure performed in Example 1 was repeated, but the hydrochloric acid additive was reduced to 5.0 grams.
  • the resulting sponges had both an increased firmness and increased resilience in comparison to the sponges produced in Example 1, wherein firmness is a qualitative measure of the compressibility of the particle. Further, the pot-life of the reaction material was decreased by about 30 seconds.
  • Example 2 The same procedure performed in Example 1 was repeated, but the hydrochloric acid additive was reduced to 2.1 grams.
  • the resulting sponges had both a decreased firmness and decreased resilience in comparison to the sponges produced in Example 1 such that the resulting sponges in the present example were significantly less “sponge-like” in comparison to the sponges produced in Example 1.
  • the instrument used was a Quanta 600 Environmental Scanning Electron Microscope manufactured by the FEI Company (Hillsboro, Oreg.) and available at the Scripps Institute of Oceanography (San Diego, Calif.).

Abstract

The present invention relates to substantially compressible, spherical porous embolization particles, including methods of making and using the particles. Further, the invention relates to embolization delivery systems for the introduction of the particle into the vascular luer.

Description

    FIELD OF THE INVENTION
  • The present invention relates to compressible embolization particles, including supplemental embolization particles, methods of making and using the particles, and delivery systems for delivery of the particles.
  • BACKGROUND OF THE INVENTION
  • Some intravascular interventional procedures produce an artificial embolism in mammals that is useful in controlling internal bleeding, blocking the blood supply to tumors, or relieving pressure in a vessel wall near an aneurysm. Known methods for producing an artificial embolism include use of (1) inflatable and detachable balloons, (2) coagulating substances, (3) later-curing polymeric substances, (4) occlusive wire coils, (5) embolization particles, and (6) supplemental occlusive embolic materials. Disadvantages relating to the known methods include recanalization, perforation of blood vessels, inadvertent downstream embolization due to fragmentation or release of trapped particles, poor positioning control, instability, imprecise sizing, and shrinkage or movement of the embolic material.
  • Early embolization particles were made by chopping or grinding polyvinyl alcohol (PVA) foam or sponge. Such PVA foam or sponge embolization particles are irregularly shaped and generally contain a range of pore sizes that are produced during the manufacturing process by whipping air into the PVA solution prior to crosslinking. Disadvantages of these particles include their non-precise size (aspect ratios) and open edges on the particles that cause them to clump together and subsequently plug up delivery catheters.
  • Spherical particles minimize these disadvantages. In addition, spherical particles can penetrate deeper into the vasculature than traditional particles due to the uniform shape of the particle. Existing spherical embolics include Biocompatibles International plc's Bead Block™, Biosphere Medical, Inc.'s Embosphere™ and Boston Scientific Corporation's Contour SE™. The Bead Block™ product is a PVA get and does not have macropores (that is, the pores are less than 1 micron in diameter). Embosphere™ is a get made of an acrylic co-polymer (trisacryl) and does not have macropores. Contour SE™ is made of PVA has an onion shape but has no surface macropores.
  • However, spherical embolization particles have several disadvantages. For example, the smooth surface of these particles may affect the stable integration of such particles within the occlusive mass comprising the particles, clotted blood and ultimately fibrous tissue. In addition, the compression of such particles is only about 20-35% in one dimension thereby limiting the size of the embolization particle that can be used in a given catheter.
  • SUMMARY OF THE INVENTION
  • The invention includes compressible substantially spherical, porous embolization particles. The interior porous extend to the particle surface to form an exterior layer having exterior pores. The compressible embolization particle preferably has a diameter from about 1,000 to 10,000 microns or more in its hydrated, fully expanded state. The particles can be compressed in one dimension to at least 50% of the diameter of the fully extended particle and in some cases can be compressed to 5% of the original diameter.
  • The compressible embolization particle is preferably radiopaque. In a preferred embodiment, the compressible embolization particle is made of a crosslinked polyvinyl alcohol (“PVA”) polymer. In some embodiments, the embolization particle also has an annular porous ring around the spherical particle which is a generated during particle formation.
  • The invention also includes an artificial embolization kit. The kit has one or more compressible embolization particle as described herein and a delivery device. The delivery device has a connection component and two syringes. The connection component is adapted to connect with the two syringes and to control the flow of fluid in the delivery device.
  • The invention includes an embolization device comprising a compressible embolization particle(s) and a delivery system such as a catheter. In some embodiments, the embolization device contains the particle in the lumen of the catheter.
  • The invention also includes a method of embolization where a percutaneous delivery system containing a compressible embolization particle is positioned so that the delivery system is in proximity to a target region of a blood vessel. The particle is compressed in the lumen of the delivery system and has a cross-sectional diameter that corresponds to the diameter of the lumen The compressed embolization particle is then ejected from the delivery system by pressure or the use of a blunt ended guidewire so that the particle is initially positioned in the target region. During or after ejection, the particle expands. The diameter of the uncompressed hydrated embolization particle is preferably chosen so that after expansion, the particle attains an expanded state that creates pressure against the interior surface of the vascular wall. The embolization particle therefore conforms to the cross section of the blood vessel.
  • The invention also includes a method of loading an embolization particle into a catheter. In this method an embolization particle is positioned in a luer hub of a catheter. A syringe containing hydration fluid is coupled to the luer hub and operated to urge the embolization particle out of the luer hub and into the catheter. The syringe is then removed. The particle is then urged through the catheter and into a target area of a patient with a guidewire.
  • In another embodiment, the invention includes a method of loading an embolization particle into a catheter where an embolization particle is positioned in a luer hub of a catheter. A stopcock is connected to the luer hub and first and second syringes are connected to the stopcock, at least one syringe initially containing hydration fluid. The first syringe is operated to urge the embolization particle out of the luer hub and into the catheter. The second syringe is operated to urge the particle through the catheter.
  • In another embodiment, the invention includes a method of embolization. In this method at least one compressible embolization particle is urged through a catheter and positioned in a target region of a blood vessel. The particle is in a compressed state while being urged through the catheter and expands to an expanded state upon exiting the catheter.
  • In another embolization method a first embolization device is positioned in a target region of a blood vessel. A second embolization device is then positioned in the blood vessel in close proximity to the first embolization device. At least one of the embolization devices is a compressible embolization particle as described herein.
  • The invention also includes a method of making a compressible embolization particle. The method includes mixing a polymer, such as PVA, a crosslinking agent, a gas and optionally a porogen to form the foam. The foam is then placed in a spherical mold having a diameter that corresponds to the desired diameter of the compressible embolization particle when hydrated for use. After curing, the particle is removed from the mold and the porogen is dissolved and separated from the particle to produce the embolization particle. In some situations, porogen is hydrolyzed in which case it is removed by rinsing.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a cross-sectional view of a spherical polyvinyl alcohol foam embolization particle, according to one embodiment of the present invention.
  • FIG. 2 is a cross-sectional view of a spherical polyvinyl alcohol foam embolization particle, according to another embodiment of the present invention.
  • FIGS. 3A, 3B and 3C are Scanning Electron Micrographs (SEM's) of a dehydrated PVA particle made according to the invention. FIG. 3A shows a substantially spherical porous particle at 80× magnification having surface pores. Some interior pores can also be seen. An annular ring can be seen encircling the “equator” of the particle. FIG. 3B is a close up (300× magnification) of the surface of the north central hemisphere of the particles in FIG. 3A. FIG. 3C depicts a cross section of a dehydrated PVA compressible particle at 80× magnification.
  • FIG. 4 is a side view of a delivery system, according to one embodiment of the present invention.
  • FIG. 5 is a perspective view of a kit containing a delivery system and an embolization particle, according to one embodiment of the present invention.
  • FIG. 6 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with an embolization coil, according to one embodiment of the present invention.
  • FIG. 7 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with two embolization coils, according to one embodiment of the present invention.
  • FIG. 8 is a side view of a supplemental embolization particle positioned in a blood vessel in conjunction with embolization particles, according to one embodiment of the present invention.
  • DETAILED DESCRIPTION
  • One problem with the larger embolization particles in the prior art is that they require larger catheters for delivery to the patient. However, the compressibility of the particles of the present invention eliminates the need for larger catheters, making it possible to deliver relatively large particles through small catheters. Further, smaller particles of the present invention are also beneficial because such particles can be used with smaller catheters for delivery.
  • The compressible particles can be used for use in the creation of an artificial embolism that can be used to treat aneurysms, tumors, bleeding, vascular malformations, or otherwise be used to block blood flow to undesired areas by occluding blood vessels. According to one embodiment, the device is a dry, dehydrated substantially spherical particle of biocompatible polyvinyl alcohol (“PVA”) foam material that when hydrated is compressible from its original hydrated volume to a constrained or smaller volume that can subsequently expand back toward the original volume. This compressibility allows the particle to be compressed in a delivery catheter having a diameter that is smaller than the diameter of the hydrated and expanded particle.
  • For purposes of this application, compressibility is defined as the ratio of the amount of the diameter of the particle that has been compressed to the total diameter of the particle in its fully expanded state. For example, a particle that has a diameter of 4 mm in its fully expanded state that can be compressed to 1 mm has a structural compressibility of 75% (3 mm (the amount of the particle diameter that the particle was compressed) divided by 4 mm (the total diameter of the particle in its expanded state)=75%).
  • Depending on the choice of catheter internal lumen diameter and the diameter of the hydrated particle, the particle can be compressed to a diameter perpendicular to the catheter lumen that is about 5% to about 90%, about 25% to about 85%, and about 40% to about 80% of the diameter of the expanded particle. This does not include the annular ring, if present.
  • The compressed particle is delivered to a target region of a blood vessel by an embolization device comprising a catheter and the compressible particle. Prior to the embolization procedure, the compressible particle is placed in the catheter lumen in a compressed state. After ejection from the lumen, the particle expands to provide for mechanical fixation of the particle within the vascular area, thereby providing occlusion of the vascular area.
  • FIG. 1 depicts an expandable embolization particle 10, according to one embodiment of the present invention. Particle 10 is preferably made of expandable PVA foam material and has a compressible, porous, spherical structure. In one aspect, the expandable material is formalin crosslinked PVA foam. Alternatively, the particle 10 can be made of polyurethane. In another aspect of the invention, the particle 10 can have any shape with a circular profile configured to provide a sealed occlusion with respect to the blood vessel in which it is positioned. For example, the particle 10 according to one embodiment can be cylindrical.
  • The particle 10 has an interior or inner portion 12 and a exterior layer 14 (also referred to as an “exterior portion” or “skin”). The interior portion 12 is more porous and contains pores with a larger diameter in comparison to the pores present in the skin 14. According to one embodiment, the pores in the exterior layer 14 have a diameter that is generally smaller than the diameter of the pores found the interior portion 12. In other words, the exterior layer 14 pores have a diameter that is generally smaller than the diameter of the pores found in the interior portion 12 of the particle. According to one embodiment, the pores in the interior portion of the particle are “macropores” having diameters of 10, 25, 50, 100, 200, 300, 400 or 500 microns or more. In some embodiments, the skin 14 has fewer pores, fewer and smaller pores, or no pores in comparison to the interior portion.
  • In a further aspect of the invention at least a portion of the pores of the interior portion are interconnected. “Interconnected pores” (also referred to as “open pores”) as used in the present application refers to pores that are in fluid communication within a solid material. The interconnected pores define an open, interconnected architecture of volume elements within the particle that can contain liquid in the hydrated state or gas in a dehydrated state.
  • The particles of the present invention are substantially spherical. The term “substantially spherical” as used herein refers to a generally spherical shape having a maximum diameter/minimum diameter ratio of from about 1.0 to about 2.0, more preferably from about 1.0 to about 1.5, and most preferably from about 1.0 to about 1.2. This definition is intended to include true spherical shapes and ellipsoidal shapes, along with any other shapes that are encompassed within the maximum diameter/minimum diameter ratio.
  • FIGS. 3A, 3B and 3C are scanning electron micrographs (SEM's) of a dehydrated PVA particle made according to the invention. FIG. 3A shows a substantially spherical porous particle at 80× magnification having surface pores. Some interior pores can also be seen. An annular ring can be seen encircling the “equator” of the particle. The annular ring is an artifact formed during curing in the joint between the two halves of the mold used to make the particle. The ring can be of any desired diameter by using a die to trim the ring before particle removal from one of the half molds. The annular ring is believed to impart additional stability to embolisms formed from the particles.
  • FIG. 3B is a close up (300× magnification) of the surface of the north central hemisphere of the particles in FIG. 3A. Interior pores can be readily seen. Some of the surface pores have diameters as large as about 50 microns with some having diameters as large as 100 or more microns. FIG. 3C depicts a cross section of a dehydrated PVA compressible particle at 80× magnification. The interior has some pores having a diameter from 100 to 500 microns with many of the pores having a diameter less than about 100 micron. The minimum pore size is about 1 micron.
  • The exterior layer 14 in FIG. 1 is an outer skin that provides increased structural strength, thereby reducing risk of fragmentation. Further, the exterior layer 14 can provide reduced friction when the exterior layer 14 contacts objects such as the interior portions of delivery systems during use. Such a strong exterior layer 14 with reduced exterior friction can aid in insertion into a blood vessel and reduce risk of recannalization and further, unintended embolization caused by debris that may be trapped in the larger inner pores. In one aspect of the invention, the relatively fewer, smaller, or lack of pores in the skin 14 enhance the structural strength and friction reducing characteristics of the skin 14. The structural strength of the skin results in a particle exhibiting much greater compressive size reduction by allowing for an interior portion having larger, more compressible pores and a foam with memory, wherein “memory” refers to the capacity of the particle to recover toward its original shape after deformation (elastic recovery). That is, the particle has memory because it can be compressed to a smaller diameter and upon release of the compressive force will return toward its original non-compressed diameter.
  • The particles of the present invention can be produced in the following manner. According to one embodiment, a PVA solution is mixed with a porogen. The amount of PVA in solution prior to mixing is preferably about 21%. Alternatively, the amount of PVA in solution can range from about 5% to about 24%.
  • The term “porogen” refers to a pore forming material dispersed in the polymer solution and subsequently removed to yield pores, voids, or free volume in the material. According to one embodiment, the porogen is starch that can be solubilized after particle formation. Alternatively, the porogen can be, but is not limited to, carbon dioxide, polyethylene glycol, or any of the inert gases.
  • After the PVA and porogen are mixed, a crosslinking component and crosslinking catalyst are added. The crosslinking component can be formaldehyde and the catalyst can be hydrochloric acid. Alternatively, the catalyst can be an acid such as sulfuric acid or, in a further alternative, almost any known mineral acid.
  • After the crosslinking component and catalyst are added to the mixture, air or any other inert gas is then added or “whipped” into the mixture to create a foam. The air is preferably added to the mixture using a high speed mixer. A single element egg beater in a high speed air motor (7,000±400 rpm) can be used to make the foam before the mixture has cross linked to any significant degree. The mixing continues until the mixture stops expanding. According to one embodiment, the foam stops expanding after about 30 seconds of mixing. Alternatively, the mixing period lasts for from about 5 seconds to about 4 minutes. In a further alternative, the mixing period lasts for from about 10 seconds to about 1 minute.
  • Subsequently, the reaction mixture of PVA, porogen, and air is placed into a mold and heated for about five hours. Alternatively, the mixture is heated for a period of time ranging from about three hours to about ten hours. In a further alternative, the mixture is heated for a period of time ranging from about 4 hours to about 7 hours. It is understood that crosslinking begins to occur after the addition of the crosslinking component and the crosslinking catalyst such that the resulting product removed from the mold comprises crosslinked PVA.
  • The mold, according to one embodiment, is a polypropylene mold defining a substantially spherical void, thereby producing a substantially spherical particle. Of course, this definition is intended to include true spherical shapes and ellipsoidal shapes, along with any other shapes that are encompassed within the maximum diameter/minimum diameter ratio.
  • The reaction mixture is injected into the spherical void. The mold, in accordance with one embodiment, has a bleed hole in communication with the spherical void to allow for excess mixture to drain from the void as necessary. According to one embodiment, the mixture is injected using a syringe. In one embodiment, a volume of the mixture greater than the volume of the void is injected such that the portions of the mixture in contact with the mold are compressed or placed under pressure, thereby forcing some portion of the mixture to escape through the bleed hole. The compression or pressure placed upon the exterior portions of the mixture ensures that the entire void is filled with mixture and that the mixture contacts all or substantially all of the surface of the mold defining the void, thereby ensuring a smooth, skin or surface to the resulting particle that can contain pores or a relatively nonporous skin. According to one embodiment, the polypropylene in the mold further enhances the smooth—even, in some cases, glossed—finish of the resulting particle. The resulting particle consists of an interior portion having larger pores as a result of the relatively unconstrained, non-compressed formation in away from the surface of the mold and an exterior layer or skin that is compacted, relatively smooth, and finished as a result of the compression on those areas of the mixture caused by contact with the mold, though one or more macropores may be present in the skin.
  • In one aspect of the invention, the mold has two components, both of which define a hemispherical void. In this embodiment, the reaction mixture is injected into both voids in excess such that when the two molds are coupled to define a spherical void, the mixture is compressed or pressured in the void and the excess mixture is forced out of the bleed hole in communication with the void. Again, the result of the compression or pressure is a particle with a relatively nonporous or microporous skin or surface with a substantially smooth finish.
  • In use, a particle or particles of the present invention can be positioned in a target region of a blood vessel to occlude the vessel. According to one embodiment, the method includes delivery of the particle to the target region with a delivery system.
  • Prior to delivery of the particle, according to one embodiment of the present invention, the user or physician can perform angiography to determine the vascular supply to the target area. Further, the resulting angiogram can be used to determine the appropriate route for delivery system insertion.
  • In accordance with another embodiment, another pre-delivery step is hydration of the embolization particle. The particle is hydrated by adding hydration fluid to the particle in a container—or placing the particle in an amount of hydration fluid in a container. Optionally, the particle may be compressed while it is in the fluid. As the particle expands from its compressed state to its expanded state, hydration fluid is drawn into the voids or pores in the interior portions of the particle, thereby accelerating hydration of the particle. According to one embodiment, this hydration process can be performed in a period of about 5 seconds. Alternatively, the process can be performed in a period ranging from about 2 seconds to about 10 seconds. The hydration fluid is any known fluid for hydrating embolization particles including contrast agent, saline, or any combination thereof, where it is understood that the term “saline” encompasses any salt solution acceptable for physiological use. It is understood that hydration fluid, may contain contrast agent or may be a contrast agent. For example, the hydration fluid can be a contrast agent such as Oxilan 300®.
  • Delivery of the particle, according to one embodiment, includes positioning the delivery system such that the system is in fluid communication with the target area of the blood vessel. In one aspect of the invention, the delivery system comprises a catheter.
  • The delivery process further includes placing a compressible embolization particle into a lumen of the delivery system. In one aspect of the invention, the diameter of the particle in its expanded state is greater than the inner diameter of the lumen of the delivery system such that the particle is in a compressed state in the lumen.
  • The particle is then delivered to the target region by ejecting or expelling the particle from the lumen of the delivery system. Upon exit from the lumen into the target area, the particle expands from its compressed state toward its expanded state. As depicted in FIG. 2, the particle 20 is configured such that the diameter of the target region of the blood vessel 22 is greater than the diameter of the lumen but less than the diameter of the particle 20 in its fully expanded state such that the particle 20 upon exiting the delivery system expands until the exterior 24 of the particle 20 contacts the inner wall 26 of the vessel 22. In one aspect of the invention, the diameter of the vessel 22 as described above results in the particle 20 being in a compressed state (though not as compressed as in the lumen of the delivery system), thus resulting in the particle 20 exerting a continuous outward pressure on the inner wall 26 of the blood vessel. This pressured contact between the particle 20 and the blood vessel 22 can help to stabilize the particle 20 in a single position within the target area of the blood vessel 22, thereby resulting in occlusion of the vessel 22. According to one embodiment, the pressured contact works to retain the particle 20 in the single position in the vessel 22 such that a substantial force is required to move the particle 20. Alternatively, the pressured contact results in the substantial mechanical fixation of the particle 20 in a single position in the blood vessel 22. In one embodiment, additional mechanical fixation occurs as a result of the blood clotting caused by the presence of the particle and by the PVA material, and further occurs as a result of the subsequent healing process. The blood clotting forms on both sides of the particle or at least downstream of the particle, thereby providing further mechanical fixation. Further, during the healing process, the immune system of the human body recognizes that the particle is a foreign object and attempts to form tissue around the particle, thereby providing further mechanical fixation.
  • According to one embodiment, the first step in delivering the particle of the present invention to the target region is positioning a catheter in a patient such that the distal end of the catheter is located at or near the target region in the patient's blood vessel. In one alternative embodiment, the catheter has a stopcock at the proximal end of the catheter configured to close off the catheter to prevent loss of blood through the catheter prior to delivery of a particle of the present invention through the catheter. In another alternative, a stopcock is placed on the proximal end of the catheter after the catheter is positioned in the patient to prevent blood loss through the catheter.
  • Once the catheter is positioned appropriately, the embolization particle of the present invention is positioned in the connection portion of the catheter (not shown), which is located at the proximal end of the catheter. According to one embodiment, the connection portion of the catheter is a luer connector hub such that the particle is positioned in the connector hub. Alternatively, in embodiments in which a stopcock is positioned on the proximal end of the catheter as described above, the connection portion of the catheter is the stopcock.
  • The particle of the present invention, in one aspect of the invention, has a diameter that is smaller than the inner diameter of the connection portion of the catheter but larger than the inner diameter of the catheter lumen such that the particle is easily positioned in the hub but requires force to be urged into the catheter lumen. The next step, therefore, is to urge the particle from the luer connector hub into the catheter lumen. According to one embodiment, the particle is urged into the catheter lumen using a syringe containing hydration fluid. That is, with the particle positioned in the connector hub of the catheter, a syringe is connected with the hub, thereby locking or enclosing the particle into the connection between the hub and the syringe. The plunger of the syringe is then depressed, providing a hydraulic force that moves the particle into the catheter lumen.
  • According to one embodiment, the particle is then urged along the catheter lumen and urged out of the catheter and into the target region using a blunt-ended guidewire. The syringe used to load the particle into the lumen is removed from the catheter. It is possible to remove the syringe without blood loss through the catheter because the particle, having in its expanded state a larger diameter than the lumen of the catheter, has sealed the lumen of the catheter. Once the syringe is removed, a guidewire is inserted into the proximal portion of the catheter and contacts the particle, urging it toward and ultimately out of the distal end of the catheter and into the target region of the patient's blood vessel.
  • Alternatively, the particle can be delivered using a delivery system instead of a guidewire. FIG. 4 depicts a delivery system or device 30, according to one embodiment of the present invention. The device 30 has a connection component 32 which, in this embodiment, is a three-way stopcock. The coupling portion 38 of the connection component 32 is coupled to a catheter (not shown). Syringes 34 and 36 are coupled to the stopcock 32. FIG. 5 depicts an alternative embodiment in which the delivery system is provided as a kit 40. The kit 40 includes two syringes 42 and 44, a connection component 46, and a vial 48 containing at least one embolization particle.
  • Using the delivery system 30 of FIG. 4 for exemplary purposes, the delivery system 30 can be used in the following manner, according to one embodiment of the present invention. First, as described above, the embolization particle is positioned in the connection portion of the catheter. With the particle positioned in the hub, the coupling portion 38 of the connection component 32 of the delivery device 30 is coupled to the luer connection hub of the catheter (not shown), thereby enclosing the embolization particle within the connection between the coupling portion 38 and the luer connection hub of the catheter (not shown).
  • According to one embodiment, one of the two syringes 34 or 36 contains hydration fluid and the other of the two syringes 34 or 36 is empty. For purposes of this example, syringe 36 is a 1 ml syringe that contains hydration fluid, while syringe 34 is empty. However, according to another embodiment, syringe 36 is empty and syringe 34 contains hydration fluid. With the particle positioned within the coupling space of the coupling portion 38 and the catheter luer connection hub (not shown), the stopcock 32 is adjusted such that the syringe 36 is in fluid communication with the syringe 34 and a small amount of hydration fluid is transferred from the syringe 36 to the empty syringe 34. According to one embodiment, 0.1 ml of hydration fluid is transferred to the syringe 34. Alternatively, any small amount ranging from about 0.05 ml to about 1.0 ml can be transferred. Alternatively, an amount of hydration fluid ranging from about 0.1 to about 0.5 ml can be transferred. The stopcock 32 is then adjusted such that the syringe 34 is in fluid communication with only the catheter lumen. With the syringe 34 in fluid communication with the catheter lumen, the user injects the small amount of hydration fluid from the syringe 34 into the catheter, thereby loading the particle into the catheter lumen. According to one embodiment, the user pushes the plunger of syringe 34 quickly and forcefully, thereby urging the particle into the lumen. In one alternative embodiment, the step of transferring a small amount of hydration fluid to the syringe 34 and then forcefully injecting the small amount into the catheter, thereby loading the particle, can be repeated once or twice to insure loading of the particle.
  • Once the particle is positioned within the catheter lumen, the particle is urged through the catheter using a syringe containing hydration fluid. According to one embodiment, syringe 34 is used to urge the particle along the catheter. Alternatively, the stopcock 32 can be adjusted such that syringe 36 containing hydration fluid is in fluid communication with the catheter lumen and syringe 36 can be used to urge the particle along the catheter. In a further alternative, the delivery device 30 is removed from the catheter and another, separate syringe containing hydration fluid is connected to the catheter and used to urge the particle through the catheter. Alternatively, a guidewire is used to urge the particle through the catheter.
  • According to an alternative embodiment, the present invention relates to a supplemental occlusion particle configured to enhance the treatment of aneurysms, tumors, bleeding, and otherwise completely block blood flow to undesired anatomical areas by supplementing the occlusion of blood vessels. This embodiment of the invention relates to the introduction of a secondary, supplemental compressible embolic device into a target area of a blood vessel to compliment the action of one or more primary embolic devices or materials. Such primary embolic devices can be smaller embolization particles such as Microstat™ (Surgical Corporation); Contour SE™ (Boston Scientific Corporation), Embosphere™ (Biosphere Medical Inc.) or Bead Block™ (Biocompatables International Plc), embolization coils, or liquid polymer embolization systems which cure in vivo.
  • FIG. 6 depicts a supplemental occlusion particle 50, according to an alternative embodiment of the present invention. The particle 50 is positioned to operate in conjunction with the embolization coil 52 to provide occlusion of the blood vessel 54. The particle 50 is configured to expand from a compressed state having a first volume to an expanded state having a second, relatively larger volume in comparison with the first. According to one embodiment, the particle 50 is configured to expand within the vessel 54 and thereby provide a degree of blood-flow-blocking mechanical fixation to support or enhance the embolic action of the primary device 52. According to one embodiment, the use of the supplemental particle 50 in cooperation with a primary embolization device such as the coil 52 results in complete or substantially complete occlusion and reduces or even eliminates the risk of recanalization.
  • In an alternative embodiment as depicted in FIG. 7, the particle 50 is positioned to operate in conjunction with two embolization coils 52 and 56 to provide occlusion. As shown in yet another alternative embodiment in FIG. 8, the particle 50 can also be used in conjunction with smaller embolization particles 58 or any other known embolization device.
  • The supplemental occlusion particle 50, in accordance with one aspect of the invention, is an embolic PVA particle as described above and depicted in FIG. 1, having an inner, porous portion and an outer layer comprised of fewer and/or closed pores having an average diameter that is smaller than the average diameter of the pores in the inner portion of the particle Alternatively, the supplemental occlusion particle 50 is any embolic device having materials with a highly compressible porous structure, such as crosslinked PVA foams. In a further alternative, the PVA foam can also be configured radiopaque by a variety of well known methods. In yet another alternative, the supplemental occlusion particle can be any known embolic particle or device capable of expanding radially inside the vessel and thereby providing a degree of mechanical fixation to support the blocking action of the primary embolization device to provide complete and permanent occlusion of the vessel.
  • In use, the supplemental particle can operate in the following manner. According to one embodiment, the supplemental particle is positioned in operable proximity to the primary occlusion device. That is, the supplemental particle is positioned in a location such that it operates to enhance the degree of blood-flow blockage created by the primary device. The supplemental particle is positioned using a delivery method or system. According to one embodiment, the particle is positioned using a guidewire as described herein. Alternatively, the particle is positioned using one of the systems depicted in FIG. 4 or 5 or a similar system. The delivery system is positioned with respect to the target area of the blood vessel to allow for positioning the particle in the target area. The particle is placed in the lumen of the delivery system which, according to one embodiment, is a catheter. The lumen has a smaller inner diameter than the diameter of the particle in its expanded state. As such, the particle is retained in a compressed state by the lumen. The particle is then expelled or ejected from the lumen of the delivery device into the blood vessel at the target area such that it is positioned in operable proximity with the primary device. Upon or during exit from the lumen, the supplemental particle expands in the blood vessel.
  • Tables I-VI compare the compressibility and catheter compatibility of Embosphere™ particles (Tables I and II), Contour SET™ particles (Tables III and IV) and Maxistat™ particles (which are within the scope of the invention) (Tables V and VI).
  • Although the present invention has been described with reference to preferred embodiments, persons skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
    TABLE I
    CATHETER COMPATIBILITY OF EMBOSPHERE MICROSPHERES
    From Their Catheter Compatibility Chart Embosphere Microspheres (microns)
    Catheter ID (inches) Catheters MFG 40-120 100-300 300-500 500-700 700-900 900-1200
    0.035-0.038 All 4Fr and 5F X X X X X X
    0.028 EmboCath BioSphere X X X X X
    0.024-0.027 Terumo
    Progreat Bost Sci
    FasTracker-325 Bost Sci
    Renegade Hi-Flo Cordis X X X X X
    MassTransit Micro
    Rebar-027 Ther
    0.019-0.023 RapidTransit Cordis
    Renegade Bost Sci X X X X
    TurboTracker-18 Bost Sci
    0.014-0.018 Regatta Cordis
    Prowler-10 Cordis X X X
    Prowler-14 Cordis
    Tracker Excel-14 Bost Sci
    0.008-0.130 Spinnaker Elite 1.5 Bost Sci
    Spinnaker Elite 1.8 Bost Sci X X
    Magic 1.5 Balt
  • TABLE II
    COMPRESSIBILITY OF EMBOSPHERE MICROSPHERES
    EMBOSPHERE
    High End
    High End of Particle
    of Particle Range in Embosphere Compatible
    Range in Microns Inches Smallest ID Size (Inches) Compression1
    300 0.011811 0.008 32.3%
    500 0.019685 0.014 28.9%
    700 0.027559 0.019 31.1%
    900 0.035433 0.024 32.3%
    1200 0.047244 0.035 25.9%

    1Embosphere Catheter Compatibility Chart states up to 33% compression
  • TABLE III
    CATHETER COMPATIBILITY OF CONTOUR SE MICROSPHERES
    From Their Catheter Compatibility Chart Contour SE Microspheres (microns)
    Catheter ID Including Catheters MFG 100-300 300-500 500-700 700-900 900-1200
    0.038 Selective 4Fr and 5F Bost Sci X X X X X
    0.024 FasTracker-325 Bost Sci X X X X
    Renegade Hi-Flo
    0.021 Renegade-18 Bost Sci X X X
    0.013 Excelisor SL-10 Bost Sci X X
    0.011 Spinnaker Elite 1.5Fr Bost Sci X
  • TABLE IV
    COMPRESSIBILITY OF CONTOUR SE PARTICLES
    CONTOUR SE
    High End
    of Particle
    High End of Particle Range in Contour SE Compatible
    Range in Microns Inches Smallest ID Size (Inches) Compression
    300 0.011811 0.011  6.9%
    500 0.019685 0.013 34.0%
    700 0.027559 0.021 23.8%
    900 0.035433 0.024 32.3%
    1200 0.047244 0.038 19.6%
  • TABLE V
    Compressibility of Surgica Maxistat Particles(1)
    MaxiStat
    Catheter Dehydrated
    Particle Smallest Particles Size Calculated % Swelling
    Hydrated Particle Size in ID Size Range upon Hydration in
    Product Size (microns) Inches (Inches) Compression in microns Mean saline
    MaxiStat 2500 2500 0.098425 0.027 72.6% 1875 2250 2062.5 21.2%
    MaxiStat 3000 3000 0.11811 0.035 70.4% 2250 2625 2437.5 23.1%
    MaxiStat 3500 3500 0.137795 0.035 74.6% 2625 2800 2712.5 29.0%
    MaxiStat 4000 4000 0.15748 0.035 77.8% 2800 3200 3000 33.3%

    (1)The Maxistate particles are substantially spherical porous embolization particles made by Surgica Corporation (El Dorado Hills, CA)
  • TABLE VI
    Maxistat ™ PVA Foam Embolization Particles
    (microns)
    Catheter 1,875- 2,250- 2,625- 2,800-
    ID Catheters MFG 2,250 2,625 2,800 3,200
    0.038 Soft-Vu AngioDynamics
    Simmons X X X X
    “Sidewinder”
    ST
    0.035 Mariner AngioDynamics
    Hydrophilic
    Coated X X X X
    Simmons-
    “Sidewinder”
    0.027 Slip-Cath Cook
    Infusion X
    Catheter
  • EXAMPLES Example 1
  • A crosslinked PVA embolization particle was prepared in the following manner. A mixture of 26.2 grams of PVA and 98.9 grams of deionized water was rapidly heated to 100° C. and held for 12 minutes. Subsequently, 39.9 grams of the resulting PVA solution was transferred for reaction purposes into a reaction kettle (a glass beaker) and set aside and allowed to cool. Separately, a mixture of 15 grams of rice starch and 135 grams of deionized water was heated to 80° C. and then 9.5 grams of the material was added to the PVA solution and thoroughly mixed. To this resulting mixture was added 3.6 grams of concentrated hydrochloric acid and 6.4 grams of about 37% formaldehyde (formalin solution) to form the reaction solution.
  • The reaction solution was then placed in a 2 liter glass reaction kettle and mixed at about 7000 rpm with a high-speed mixer having a high-speed air motor and using a mixing blade to whip air into the mixture until the foam stopped expanding and the resulting mixture achieved an appearance similar to whipped cream, which required about 30 seconds of mixing. The mixing blade was similar in configuration to an egg beater.
  • After mixing, the reaction mixture was transferred to spherical molds of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm diameter and allowed to cure for 5 hours at 55° C. The polypropylene molds used in this example have two identical 1 inch by 1 inch square pieces that are 0.2 inches in thickness. Each piece defines a hemisphere on one side, wherein the hemisphere is sized according to the desired size of the embolization particle. Further, each piece also defines a 0.039 inch bleed hole in fluid communication with the hemisphere, thereby allowing relief of any overfill amount through the bleed hole.
  • The resulting products were partially acetalized crosslinked PVA sponges, which were then thoroughly washed to remove excess formaldehyde and hydrochloric acid. Certain portions of the resulting sponges were then removed, including the center ring and the poles (flashing), to create substantially spherical particles of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm in diameter in their hydrated, fully expanded state. The sponges were then dried for 16.5 hours at 50° C. to complete the manufacturing process.
  • Example 2
  • The same procedure performed in Example 1 was repeated, but the formaldehyde additive was reduced to 5.2 grams. It was believed that the reduction in formaldehyde would change the pot-life of the reaction solution, wherein “pot-life” is intended to mean the useful life of the mixture (after some period of time, the mixture ages to the point that it cannot be used to create a particle of the present invention). However, no significant change in pot-life was observed.
  • Example 3
  • The same procedure performed in Example 1 was repeated, but the hydrochloric acid additive was reduced to 5.0 grams. The resulting sponges had both an increased firmness and increased resilience in comparison to the sponges produced in Example 1, wherein firmness is a qualitative measure of the compressibility of the particle. Further, the pot-life of the reaction material was decreased by about 30 seconds.
  • Example 4
  • The same procedure performed in Example 1 was repeated, but the hydrochloric acid additive was reduced to 2.1 grams. The resulting sponges had both a decreased firmness and decreased resilience in comparison to the sponges produced in Example 1 such that the resulting sponges in the present example were significantly less “sponge-like” in comparison to the sponges produced in Example 1.
  • Example 5 SEM Images
  • The instrument used was a Quanta 600 Environmental Scanning Electron Microscope manufactured by the FEI Company (Hillsboro, Oreg.) and available at the Scripps Institute of Oceanography (San Diego, Calif.).
  • All samples were prepared (methods well known in the art) by Critical Point Drying, exchanging 200 proof ethanol for the saline hydration fluid, then exchanging the ethanol with liquid CO2 (4×), then finally heating to drive the CO2 off as a gas. The samples were then transferred to carbon tape and sputter coated with gold/palladium. The samples were then imaged under high vacuum SEM. FIG. 3A-3C were made according to this protocol.

Claims (26)

1. A compressible embolization particle comprising a substantially spherical porous particle having pores that extend to the surface of said particle wherein said particle has a diameter ranging from about 1,000 microns to about 10,000 microns when hydrated and fully expanded.
2. The particle of claim 1, wherein the particle has a diameter ranging from about 2,000 microns to about 4,500 microns when hydrated and fully expanded.
3. The particle of claim 1, wherein the particle has a diameter ranging from about 3,000 microns to about 4,000 microns when hydrated and fully expanded.
4. The particle of claim 1, wherein the particle comprises a PVA polymer.
5. The particle of claim 1, wherein said particle is hydrated.
6. The particle of claim 5, wherein said particle can be compressed in one dimension to about 80% of the diameter of the hydrated particle.
7. The particle of claim 5, wherein said particle can be compressed in one dimension to about 25% of the diameter of the hydrated particle.
8. The particle of claim 1, wherein the surface or interior pores of a dehydrated particle can have a diameter of 50 microns or more.
9. The particle of claim 1, wherein the surface or interior pores of a dehydrated particle can have a diameter of 100-microns or more.
10. The particle of claim 1, further comprising a porous annular ring around said particle.
11. An embolization device comprising the embolization particle of claim 1 and a catheter having a lumen to receive said particle.
12. The device of claim 11, wherein the embolization particle is disposed in the lumen of said catheter.
13. The device of claim 12, further comprising a 3-way connection component operably coupled to the catheter, and two syringes operably coupled to the 3-way connection component.
14. A method of embolization comprising:
positioning a distal portion of the embolization device of claim 12 in proximity to a target area of a blood vessel, and
ejecting the particle from the lumen of said embolization device such that the particle is positioned in the target area.
15. The method of claim 14, wherein the particle expands from its compressed state to an expanded state upon ejection from said lumen.
16. The method of claim 15, wherein the non-compressed particle has a diameter that is greater than an inner diameter of the target area of the blood vessel.
17. The method of claim 16, wherein the particle in the expanded state is substantially fixed in position in the vessel.
18. A method of loading an embolization particle into a catheter comprising:
positioning an embolization particle of claim 1 in a luer hub of a catheter;
coupling a syringe containing hydration fluid to the luer hub;
operating the syringe to urge the embolization particle out of the luer hub and into the catheter;
removing the syringe from the luer hub; and
urging the embolization particle through the catheter and into a target area of a patient with a guidewire.
19. A method of loading an embolization particle into a catheter comprising:
positioning an embolization particle of claim 1 in a luer hub of a catheter;
coupling a three-way stopcock to the luer hub, wherein the stopcock is coupled to a first and a second syringe, wherein one or both of the syringes initially contain hydration fluid;
operating the first syringe to urge the embolization particle out of the luer hub and into the catheter; and
operating the second syringe to urge the embolization particle through the catheter and into a target area of a vessel.
20. A method of embolization comprising
providing at least one embolization particle of claim 1;
urging the embolization particle through a catheter wherein the particle is in a compressed state; and
positioning the embolization particle in a target vascular area, wherein the particle expands to an expanded state upon exiting the catheter.
21. The method of claim 20, wherein the urging of the particle through the catheter is a guidewire.
22. The method of claim 20, wherein the urging of the particle through the catheter comprises applying fluid pressure to the particle.
23. A method of embolization comprising:
positioning a first embolization device in a target vascular area; and
positioning a second embolization device in proximity to the first embolization device, wherein at least one of said embolization devices comprise the embolization particle of claim 1.
24. A method of making a compressible embolization particle, comprising:
mixing polyvinyl alcohol (“PVA”), a porogen, and a gas to form a foam; and
injecting the foam into a mold.
25. The method of claim 24, wherein the mold is a hollow sphere formed from two halves of a sphere.
26. The method of claim 24, further comprising trimming the annular ring formed at the junction of said two halves.
US11/669,119 2006-01-30 2007-01-30 Compressible intravascular embolization particles and related methods and delivery systems Abandoned US20080033366A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/669,119 US20080033366A1 (en) 2006-01-30 2007-01-30 Compressible intravascular embolization particles and related methods and delivery systems
US13/717,452 US10448955B2 (en) 2006-01-30 2012-12-17 Compressible intravascular embolization particles and related methods and delivery systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76482506P 2006-01-30 2006-01-30
US11/669,119 US20080033366A1 (en) 2006-01-30 2007-01-30 Compressible intravascular embolization particles and related methods and delivery systems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US76482506P Continuation 2006-01-30 2006-01-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/717,452 Division US10448955B2 (en) 2006-01-30 2012-12-17 Compressible intravascular embolization particles and related methods and delivery systems

Publications (1)

Publication Number Publication Date
US20080033366A1 true US20080033366A1 (en) 2008-02-07

Family

ID=38229838

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/669,119 Abandoned US20080033366A1 (en) 2006-01-30 2007-01-30 Compressible intravascular embolization particles and related methods and delivery systems
US13/717,452 Active 2027-10-08 US10448955B2 (en) 2006-01-30 2012-12-17 Compressible intravascular embolization particles and related methods and delivery systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/717,452 Active 2027-10-08 US10448955B2 (en) 2006-01-30 2012-12-17 Compressible intravascular embolization particles and related methods and delivery systems

Country Status (3)

Country Link
US (2) US20080033366A1 (en)
EP (1) EP1986707A2 (en)
WO (1) WO2007090127A2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US20060063732A1 (en) * 2000-03-24 2006-03-23 Jean-Marie Vogel Compositions and methods for gene therapy
US20060251582A1 (en) * 2005-05-09 2006-11-09 Biosphere Medical Sa Compositions and methods using microspheres and non-ionic contrast agents
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
US20080118569A1 (en) * 2000-03-20 2008-05-22 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US20090117196A1 (en) * 1998-10-16 2009-05-07 Biosphere Medical, Inc. Polyvinyl Alcohol Microspheres, Injectable Solutions and Therapeutic Uses of the Same
US20110033508A1 (en) * 1998-03-06 2011-02-10 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
US20110319753A1 (en) * 2010-06-25 2011-12-29 Aidan Marcus Tout Systems and methods for imaging sinuses
US8142815B2 (en) 2000-03-20 2012-03-27 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20140135811A1 (en) * 2012-11-13 2014-05-15 Covidien Lp Occlusive devices
US8932637B2 (en) 2000-03-20 2015-01-13 Biosphere Medical. Inc. Injectable and swellable microspheres for tissue bulking
US20150105817A1 (en) * 2008-05-02 2015-04-16 Sequent Medical Inc. Filamentary devices for treatment of vascular defects
US9198670B2 (en) 2013-08-16 2015-12-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US9259337B2 (en) 2007-06-04 2016-02-16 Sequent Medical, Inc. Methods and devices for treatment of vascular defects
US9358140B1 (en) 2009-11-18 2016-06-07 Aneuclose Llc Stent with outer member to embolize an aneurysm
US9408916B2 (en) 2013-09-19 2016-08-09 Microvention, Inc. Polymer films
US9546236B2 (en) 2013-09-19 2017-01-17 Terumo Corporation Polymer particles
US9629635B2 (en) 2014-04-14 2017-04-25 Sequent Medical, Inc. Devices for therapeutic vascular procedures
US9688788B2 (en) 2013-11-08 2017-06-27 Terumo Corporation Polymer particles
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
US9955976B2 (en) 2013-08-16 2018-05-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US10028747B2 (en) 2008-05-01 2018-07-24 Aneuclose Llc Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm
US10071181B1 (en) 2015-04-17 2018-09-11 Teleflex Innovations S.À.R.L. Resorbable embolization spheres
US10201632B2 (en) 2016-09-28 2019-02-12 Terumo Corporation Polymer particles
US10448955B2 (en) 2006-01-30 2019-10-22 Biosphere Medical, Inc. Compressible intravascular embolization particles and related methods and delivery systems
US10716573B2 (en) 2008-05-01 2020-07-21 Aneuclose Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm
US11291453B2 (en) 2019-03-15 2022-04-05 Sequent Medical, Inc. Filamentary devices having a flexible joint for treatment of vascular defects
US11317921B2 (en) 2019-03-15 2022-05-03 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11559309B2 (en) 2019-03-15 2023-01-24 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11633818B2 (en) 2019-11-04 2023-04-25 Covidien Lp Devices, systems, and methods for treatment of intracranial aneurysms
US11707371B2 (en) 2008-05-13 2023-07-25 Covidien Lp Braid implant delivery systems
US11844528B2 (en) 2008-04-21 2023-12-19 Covidien Lp Multiple layer filamentary devices for treatment of vascular defects

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780246B2 (en) * 2014-09-12 2020-09-22 Callisyn Biomedical, Inc. Vascular microcatheter

Citations (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673125A (en) * 1969-05-10 1972-06-27 Kanegafuchi Spinning Co Ltd Method of producing polyvinyl acetal porous articles
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4090010A (en) * 1970-12-11 1978-05-16 Porvair Limited Water vapor permeable microporous sheet materials and their method of manufacture
US4268495A (en) * 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4320040A (en) * 1978-09-07 1982-03-16 Sumitomo Chemical Company, Limited Method for preparing highly absorbent hydro-gel polymers
US4350773A (en) * 1979-08-14 1982-09-21 Mitsubishi Chemical Industries, Limited Weakly acidic cation exchange resin and process for producing same
US4367323A (en) * 1980-12-03 1983-01-04 Sumitomo Chemical Company, Limited Production of hydrogels
US4657553A (en) * 1984-07-24 1987-04-14 Taylor David E M Chemical substances
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
US4863972A (en) * 1986-07-09 1989-09-05 Mitsubishi Chemical Industries Limited Porous cross-linked polyvinyl alcohol particles, process for producing the same, and separating agent composed of the same
US4999188A (en) * 1983-06-30 1991-03-12 Solodovnik Valentin D Methods for embolization of blood vessels
US5007940A (en) * 1989-06-09 1991-04-16 American Medical Systems, Inc. Injectable polymeric bodies
US5028332A (en) * 1988-07-22 1991-07-02 Terumo Kabushiki Kaisha Hydrophilic material and method of manufacturing
US5092883A (en) * 1988-12-28 1992-03-03 Eppley Barry L Method for promoting soft connective tissue growth and repair in mammals
US5106876A (en) * 1988-09-22 1992-04-21 Terumo Kabushiki Kaisha Water-insoluble hydrogel and method for production thereof by using radiation, freezing and thawing
US5114577A (en) * 1987-12-29 1992-05-19 Mitsubishi Kasei Corporation Composite separating agent
US5116387A (en) * 1989-06-09 1992-05-26 American Medical Systems, Inc. Preparation of injectable polymeric bodies
US5158573A (en) * 1989-06-09 1992-10-27 American Medical Systems, Inc. Injectable polymeric bodies
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US5258042A (en) * 1991-12-16 1993-11-02 Henry Ford Health System Intravascular hydrogel implant
US5336263A (en) * 1992-04-06 1994-08-09 Robert A. Ersek Treatment of urological and gastric fluid reflux disorders by injection of mmicro particles
US5403870A (en) * 1989-05-31 1995-04-04 Kimberly-Clark Corporation Process for forming a porous particle of an absorbent polymer
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5470911A (en) * 1988-11-21 1995-11-28 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5550188A (en) * 1988-11-21 1996-08-27 Collagen Corporation Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates
US5554659A (en) * 1991-08-06 1996-09-10 Rosenblatt; Solomon Injection molded PVA sponge
US5593990A (en) * 1993-03-01 1997-01-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5624685A (en) * 1991-10-16 1997-04-29 Terumo Kabushiki Kaisha High polymer gel and vascular lesion embolizing material comprising the same
US5635215A (en) * 1991-05-29 1997-06-03 Biosepra S.A. Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
US5653922A (en) * 1994-06-06 1997-08-05 Biopore Corporation Polymeric microbeads and method of preparation
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US5785977A (en) * 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5798096A (en) * 1994-08-10 1998-08-25 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biocompatible hydrogel
US5823198A (en) * 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
US5891470A (en) * 1998-04-17 1999-04-06 Advanced Polymer Systems, Inc. Softgel formulation containing retinol
US5895411A (en) * 1995-01-27 1999-04-20 Scimed Life Systems Inc. Embolizing system
US5925683A (en) * 1996-10-17 1999-07-20 Target Therapeutics, Inc. Liquid embolic agents
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
US5964806A (en) * 1997-06-12 1999-10-12 Uromedica, Inc. Adjustable implantable genitourinary device
US6048908A (en) * 1997-06-27 2000-04-11 Biopore Corporation Hydrophilic polymeric material
US6060582A (en) * 1992-02-28 2000-05-09 The Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US6060530A (en) * 1996-04-04 2000-05-09 Novartis Ag Process for manufacture of a porous polymer by use of a porogen
US6191193B1 (en) * 2000-01-06 2001-02-20 Korea Institute Of Science & Technology Microspheric embolic materials having a dual structure of poly(vinyl acetate) core and poly(vinyl alcohol) shell and method for preparing the same
US6242512B1 (en) * 1996-01-18 2001-06-05 Wacker Chemie Gmbh Re-dispersible polymer powder and aqueous polymer dispersions obtainable therefrom
US6335028B1 (en) * 1998-03-06 2002-01-01 Biosphere Medical, Inc. Implantable particles for urinary incontinence
US6337198B1 (en) * 1999-04-16 2002-01-08 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US6436424B1 (en) * 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
US20030059371A1 (en) * 2001-09-27 2003-03-27 Matson Louis R. Partially acetalized polyvinyl alcohol embolizations particles, compositions containing those particles and methods of making and using them
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20030203985A1 (en) * 2002-04-04 2003-10-30 Scimed Life Systems, Inc., A Minnesota Corporation Forming a chemically cross-linked particle of a desired shape and diameter
US20030206864A1 (en) * 2000-03-06 2003-11-06 Scimed Life Systems, Inc., A Minnesota Corporation Embolic agents visible under ultrasound
US20030215519A1 (en) * 2002-05-08 2003-11-20 Alexander Schwarz Embolization using degradable crosslinked hydrogels
US20030233150A1 (en) * 2002-03-29 2003-12-18 George Bourne Tissue treatment
US6676971B2 (en) * 2000-03-13 2004-01-13 Biocure, Inc. Embolic compositions
US6680046B1 (en) * 1998-10-16 2004-01-20 Biosphere Medical, S.A. Method of embolization using polyvinyl alcohol microspheres
US6710126B1 (en) * 1999-11-15 2004-03-23 Bio Cure, Inc. Degradable poly(vinyl alcohol) hydrogels
US20040068039A1 (en) * 2001-01-19 2004-04-08 Won-Seok Lyoo Method of preparing poly(vinyl pivalate)
US20040091543A1 (en) * 2002-10-23 2004-05-13 Barbara Bell Embolic compositions
US20040092883A1 (en) * 2002-10-23 2004-05-13 Casey Thomas V. Mixing and delivery of therapeutic compositions
US20040096514A1 (en) * 1999-03-05 2004-05-20 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US20040220611A1 (en) * 2002-08-01 2004-11-04 Medcity Medical Innovations, Inc. Embolism protection devices
US20050043585A1 (en) * 2003-01-03 2005-02-24 Arindam Datta Reticulated elastomeric matrices, their manufacture and use in implantable devices
US20050085847A1 (en) * 2003-07-22 2005-04-21 Galdonik Jason A. Fiber based embolism protection device
US20050095428A1 (en) * 2003-11-04 2005-05-05 Dicarlo Paul Embolic compositions
US20050119687A1 (en) * 2003-09-08 2005-06-02 Dacey Ralph G.Jr. Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels
US20050158393A1 (en) * 2001-06-08 2005-07-21 Phillippe Reb Colloidal metal labeled microparticles and methods for producing and using the same
US20060009851A1 (en) * 2004-06-29 2006-01-12 Keith Collins Percutaneous methods for injecting a curable biomaterial into an intervertebral space
US20060052816A1 (en) * 2004-08-31 2006-03-09 Cook Incorporated Device for treating an aneurysm
US20060069168A1 (en) * 2002-10-29 2006-03-30 Norikazu Tabata Vascular embolization material
US20070005094A1 (en) * 2005-04-04 2007-01-04 Eaton Donald J Device and methods for treating paranasal sinus conditions
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US20080220077A1 (en) * 2000-03-24 2008-09-11 Biosphere Medical, Inc. Microspheres for active embolization
US20080268367A1 (en) * 2007-04-24 2008-10-30 Mridula Nair Method of making porous particles
US20090092676A1 (en) * 2007-10-03 2009-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20090186094A1 (en) * 2000-03-20 2009-07-23 Biosphere Medical, Inc. Injectable and Swellable Microspheres for Tissue Bulking
US7780645B2 (en) * 2004-10-26 2010-08-24 Codman & Shurtleff, Inc. Method of delivering embolic particles to an aneurysm
US20100222802A1 (en) * 2000-04-14 2010-09-02 Attenuex Technologies, Inc. Implant with high vapor pressure medium
US7811290B2 (en) * 2006-04-26 2010-10-12 Illuminoss Medical, Inc. Apparatus and methods for reinforcing bone
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659935A (en) 1950-03-18 1953-11-24 Christopher L Wilson Method of making compressed sponges
JPS49108168A (en) 1973-02-16 1974-10-15
JPS5294839A (en) 1976-02-05 1977-08-09 Kobe Steel Ltd Apparatus for manufacturing solid backing materials
JPS5350290A (en) 1976-10-18 1978-05-08 Sumitomo Chem Co Ltd Preparation f hydrogel
US4314032A (en) 1978-10-26 1982-02-02 Kureha Kagaku Kogyo Kabushiki Kaisha Crosslinked polyvinyl alcohol gel
JPS57128709A (en) 1981-02-03 1982-08-10 Sumitomo Chem Co Ltd Preparation of hydrogel
JPS6056676A (en) 1983-09-09 1985-04-02 Mazda Motor Corp Front suspension for automobile
US5258028A (en) 1988-12-12 1993-11-02 Ersek Robert A Textured micro implants
US5147937A (en) 1990-03-22 1992-09-15 Rohm And Haas Company Process for making controlled, uniform-sized particles in the 1 to 50 micrometer range
ES2113094T3 (en) 1993-03-09 1998-04-16 Epic Therapeutics Inc THE MACROMOLECULAR MICROPARTICLES AND METHODS OF OBTAINING.
US5702361A (en) 1996-01-31 1997-12-30 Micro Therapeutics, Inc. Method for embolizing blood vessels
US5611344A (en) 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US6315762B1 (en) * 1996-11-14 2001-11-13 Angiodynamics, Inc. Contrast medium delivery system and associated method
US6139963A (en) 1996-11-28 2000-10-31 Kuraray Co., Ltd. Polyvinyl alcohol hydrogel and process for producing the same
WO1999011196A1 (en) 1997-09-04 1999-03-11 Point Biomedical Corporation Injectable tissue reconstruction material
WO1999012577A1 (en) 1997-09-05 1999-03-18 Nycomed Imaging As Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization
US6099952A (en) 1998-02-18 2000-08-08 Xomed Surgical Products, Inc. Medical sponge having mucopolysaccharide coating
US6165193A (en) 1998-07-06 2000-12-26 Microvention, Inc. Vascular embolization with an expansible implant
US6652883B2 (en) 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
US20030212022A1 (en) 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
EP1490120B1 (en) 2002-03-29 2009-11-11 Boston Scientific Limited Embolization
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
AU2003234159A1 (en) 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
WO2003105917A2 (en) * 2002-06-12 2003-12-24 Scimed Life Systems, Inc. Bulking agents
GB0216333D0 (en) 2002-07-13 2002-08-21 Univ Cranfield Substance - selective polymer membranes
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
JP4036328B2 (en) 2002-09-30 2008-01-23 株式会社Kddi研究所 Scene classification apparatus for moving image data
CN103393605B (en) 2003-02-12 2018-05-29 生物相容英国有限公司 For the composition of the chemoembolization of solid tumor
JP4885866B2 (en) 2004-10-25 2012-02-29 セロノヴァ バイオサイエンスィズ ジャーマニー ゲーエムベーハー Fillable polyphosphazene-containing particles for therapeutic and / or diagnostic applications and methods for their preparation and use
US20060178696A1 (en) * 2005-02-04 2006-08-10 Porter Stephen C Macroporous materials for use in aneurysms
CN104815331A (en) 2005-05-09 2015-08-05 生物领域医疗公司 Compositions and methods using microspheres and non-ionic contrast agents
WO2007090127A2 (en) 2006-01-30 2007-08-09 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
WO2008014060A2 (en) 2006-07-27 2008-01-31 Boston Scientific Limited Microparticle
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
US20080208171A1 (en) 2007-02-23 2008-08-28 Argenta Louis C Device and method for removing edema
JP5294839B2 (en) 2008-12-25 2013-09-18 ユニ・チャーム株式会社 Cosmetic puff and recess forming method
EP2351779B1 (en) 2010-01-27 2019-04-24 Biosphere Medical, Inc. Microspheres and method of making the microspheres
JP6056676B2 (en) 2013-06-21 2017-01-11 富士通株式会社 Electronic device and manufacturing method thereof

Patent Citations (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673125A (en) * 1969-05-10 1972-06-27 Kanegafuchi Spinning Co Ltd Method of producing polyvinyl acetal porous articles
US4090010A (en) * 1970-12-11 1978-05-16 Porvair Limited Water vapor permeable microporous sheet materials and their method of manufacture
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4320040A (en) * 1978-09-07 1982-03-16 Sumitomo Chemical Company, Limited Method for preparing highly absorbent hydro-gel polymers
US4268495A (en) * 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4350773A (en) * 1979-08-14 1982-09-21 Mitsubishi Chemical Industries, Limited Weakly acidic cation exchange resin and process for producing same
US4367323A (en) * 1980-12-03 1983-01-04 Sumitomo Chemical Company, Limited Production of hydrogels
US4999188A (en) * 1983-06-30 1991-03-12 Solodovnik Valentin D Methods for embolization of blood vessels
US4657553A (en) * 1984-07-24 1987-04-14 Taylor David E M Chemical substances
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
US4863972A (en) * 1986-07-09 1989-09-05 Mitsubishi Chemical Industries Limited Porous cross-linked polyvinyl alcohol particles, process for producing the same, and separating agent composed of the same
US5114577A (en) * 1987-12-29 1992-05-19 Mitsubishi Kasei Corporation Composite separating agent
US5028332A (en) * 1988-07-22 1991-07-02 Terumo Kabushiki Kaisha Hydrophilic material and method of manufacturing
US5106876A (en) * 1988-09-22 1992-04-21 Terumo Kabushiki Kaisha Water-insoluble hydrogel and method for production thereof by using radiation, freezing and thawing
US5550188A (en) * 1988-11-21 1996-08-27 Collagen Corporation Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates
US5470911A (en) * 1988-11-21 1995-11-28 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5092883A (en) * 1988-12-28 1992-03-03 Eppley Barry L Method for promoting soft connective tissue growth and repair in mammals
US5403870A (en) * 1989-05-31 1995-04-04 Kimberly-Clark Corporation Process for forming a porous particle of an absorbent polymer
US5158573A (en) * 1989-06-09 1992-10-27 American Medical Systems, Inc. Injectable polymeric bodies
US5116387A (en) * 1989-06-09 1992-05-26 American Medical Systems, Inc. Preparation of injectable polymeric bodies
US5007940A (en) * 1989-06-09 1991-04-16 American Medical Systems, Inc. Injectable polymeric bodies
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5635215A (en) * 1991-05-29 1997-06-03 Biosepra S.A. Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
US5648100A (en) * 1991-05-29 1997-07-15 Assistance Publique Hopitaux De Paris Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
US5554659A (en) * 1991-08-06 1996-09-10 Rosenblatt; Solomon Injection molded PVA sponge
US5624685A (en) * 1991-10-16 1997-04-29 Terumo Kabushiki Kaisha High polymer gel and vascular lesion embolizing material comprising the same
US5258042A (en) * 1991-12-16 1993-11-02 Henry Ford Health System Intravascular hydrogel implant
US6060582A (en) * 1992-02-28 2000-05-09 The Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US6602975B2 (en) * 1992-02-28 2003-08-05 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US6306922B1 (en) * 1992-02-28 2001-10-23 Boards Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5336263A (en) * 1992-04-06 1994-08-09 Robert A. Ersek Treatment of urological and gastric fluid reflux disorders by injection of mmicro particles
US5712291A (en) * 1993-03-01 1998-01-27 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5593990A (en) * 1993-03-01 1997-01-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5760097A (en) * 1994-06-06 1998-06-02 Biopore Corporation Methods of preparing polymeric microbeds
US5653922A (en) * 1994-06-06 1997-08-05 Biopore Corporation Polymeric microbeads and method of preparation
US5863957A (en) * 1994-06-06 1999-01-26 Biopore Corporation Polymeric microbeads
US6100306A (en) * 1994-06-06 2000-08-08 Biopore Corporation Polymeric microbeads and methods of preparation
US5798096A (en) * 1994-08-10 1998-08-25 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biocompatible hydrogel
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
US5895411A (en) * 1995-01-27 1999-04-20 Scimed Life Systems Inc. Embolizing system
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US6242512B1 (en) * 1996-01-18 2001-06-05 Wacker Chemie Gmbh Re-dispersible polymer powder and aqueous polymer dispersions obtainable therefrom
US5785977A (en) * 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US6060530A (en) * 1996-04-04 2000-05-09 Novartis Ag Process for manufacture of a porous polymer by use of a porogen
US5823198A (en) * 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
US5925683A (en) * 1996-10-17 1999-07-20 Target Therapeutics, Inc. Liquid embolic agents
US5964806A (en) * 1997-06-12 1999-10-12 Uromedica, Inc. Adjustable implantable genitourinary device
US6048908A (en) * 1997-06-27 2000-04-11 Biopore Corporation Hydrophilic polymeric material
US6218440B1 (en) * 1997-06-27 2001-04-17 Biopore Corporation Hydrophilic polymeric material and method of preparation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20110033508A1 (en) * 1998-03-06 2011-02-10 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6335028B1 (en) * 1998-03-06 2002-01-01 Biosphere Medical, Inc. Implantable particles for urinary incontinence
US7060298B2 (en) * 1998-03-06 2006-06-13 Biosphere Medical, Inc. Implantable particles for the treatment of gastroesophageal reflux disease
US5891470A (en) * 1998-04-17 1999-04-06 Advanced Polymer Systems, Inc. Softgel formulation containing retinol
US20090117196A1 (en) * 1998-10-16 2009-05-07 Biosphere Medical, Inc. Polyvinyl Alcohol Microspheres, Injectable Solutions and Therapeutic Uses of the Same
US7591993B2 (en) * 1998-10-16 2009-09-22 Biosphere Medical, S.A. Polyvinyl alcohol microspheres, and injectable solutions of the same
US20100119572A1 (en) * 1998-10-16 2010-05-13 Biosphere Medical, S.A. Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same
US20040091425A1 (en) * 1998-10-16 2004-05-13 Biosphere Medical, S.A. Polyvinyl alcohol microspheres, and methods for making and therapeutic uses of the same
US6680046B1 (en) * 1998-10-16 2004-01-20 Biosphere Medical, S.A. Method of embolization using polyvinyl alcohol microspheres
US20040096514A1 (en) * 1999-03-05 2004-05-20 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6337198B1 (en) * 1999-04-16 2002-01-08 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US6710126B1 (en) * 1999-11-15 2004-03-23 Bio Cure, Inc. Degradable poly(vinyl alcohol) hydrogels
US6191193B1 (en) * 2000-01-06 2001-02-20 Korea Institute Of Science & Technology Microspheric embolic materials having a dual structure of poly(vinyl acetate) core and poly(vinyl alcohol) shell and method for preparing the same
US20030206864A1 (en) * 2000-03-06 2003-11-06 Scimed Life Systems, Inc., A Minnesota Corporation Embolic agents visible under ultrasound
US6676971B2 (en) * 2000-03-13 2004-01-13 Biocure, Inc. Embolic compositions
US20050025708A1 (en) * 2000-03-20 2005-02-03 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US6436424B1 (en) * 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20090186094A1 (en) * 2000-03-20 2009-07-23 Biosphere Medical, Inc. Injectable and Swellable Microspheres for Tissue Bulking
US6790456B2 (en) * 2000-03-20 2004-09-14 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20080118569A1 (en) * 2000-03-20 2008-05-22 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US20080220077A1 (en) * 2000-03-24 2008-09-11 Biosphere Medical, Inc. Microspheres for active embolization
US20100222802A1 (en) * 2000-04-14 2010-09-02 Attenuex Technologies, Inc. Implant with high vapor pressure medium
US20040068039A1 (en) * 2001-01-19 2004-04-08 Won-Seok Lyoo Method of preparing poly(vinyl pivalate)
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US20050158393A1 (en) * 2001-06-08 2005-07-21 Phillippe Reb Colloidal metal labeled microparticles and methods for producing and using the same
US20030059371A1 (en) * 2001-09-27 2003-03-27 Matson Louis R. Partially acetalized polyvinyl alcohol embolizations particles, compositions containing those particles and methods of making and using them
US6911219B2 (en) * 2001-09-27 2005-06-28 Surgica Corporation Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them
US20030233150A1 (en) * 2002-03-29 2003-12-18 George Bourne Tissue treatment
US20030203985A1 (en) * 2002-04-04 2003-10-30 Scimed Life Systems, Inc., A Minnesota Corporation Forming a chemically cross-linked particle of a desired shape and diameter
US20030215519A1 (en) * 2002-05-08 2003-11-20 Alexander Schwarz Embolization using degradable crosslinked hydrogels
US20040220611A1 (en) * 2002-08-01 2004-11-04 Medcity Medical Innovations, Inc. Embolism protection devices
US20040091543A1 (en) * 2002-10-23 2004-05-13 Barbara Bell Embolic compositions
US20040092883A1 (en) * 2002-10-23 2004-05-13 Casey Thomas V. Mixing and delivery of therapeutic compositions
US20060069168A1 (en) * 2002-10-29 2006-03-30 Norikazu Tabata Vascular embolization material
US20050043585A1 (en) * 2003-01-03 2005-02-24 Arindam Datta Reticulated elastomeric matrices, their manufacture and use in implantable devices
US20050085847A1 (en) * 2003-07-22 2005-04-21 Galdonik Jason A. Fiber based embolism protection device
US20050119687A1 (en) * 2003-09-08 2005-06-02 Dacey Ralph G.Jr. Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels
US20050095428A1 (en) * 2003-11-04 2005-05-05 Dicarlo Paul Embolic compositions
US7901770B2 (en) * 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7837733B2 (en) * 2004-06-29 2010-11-23 Spine Wave, Inc. Percutaneous methods for injecting a curable biomaterial into an intervertebral space
US20060009851A1 (en) * 2004-06-29 2006-01-12 Keith Collins Percutaneous methods for injecting a curable biomaterial into an intervertebral space
US20060052816A1 (en) * 2004-08-31 2006-03-09 Cook Incorporated Device for treating an aneurysm
US7780645B2 (en) * 2004-10-26 2010-08-24 Codman & Shurtleff, Inc. Method of delivering embolic particles to an aneurysm
US20070005094A1 (en) * 2005-04-04 2007-01-04 Eaton Donald J Device and methods for treating paranasal sinus conditions
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
US7811290B2 (en) * 2006-04-26 2010-10-12 Illuminoss Medical, Inc. Apparatus and methods for reinforcing bone
US20080268367A1 (en) * 2007-04-24 2008-10-30 Mridula Nair Method of making porous particles
US20090092676A1 (en) * 2007-10-03 2009-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033508A1 (en) * 1998-03-06 2011-02-10 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US9295648B2 (en) 1998-03-06 2016-03-29 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US9205053B2 (en) 1998-03-06 2015-12-08 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US8658215B2 (en) 1998-03-06 2014-02-25 Biospehere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US8673266B2 (en) 1998-10-16 2014-03-18 Biosphere Medical, S.A. Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same
US7670592B2 (en) 1998-10-16 2010-03-02 Biosphere Medical, S.A. Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same
US20090117196A1 (en) * 1998-10-16 2009-05-07 Biosphere Medical, Inc. Polyvinyl Alcohol Microspheres, Injectable Solutions and Therapeutic Uses of the Same
US8142815B2 (en) 2000-03-20 2012-03-27 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20080118569A1 (en) * 2000-03-20 2008-05-22 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US9017710B2 (en) 2000-03-20 2015-04-28 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
US8932637B2 (en) 2000-03-20 2015-01-13 Biosphere Medical. Inc. Injectable and swellable microspheres for tissue bulking
US8778333B2 (en) 2000-03-20 2014-07-15 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US10265271B2 (en) 2000-03-24 2019-04-23 Biosphere Medical, Inc. Microspheres for the treatment of a prostate hyperplasia by active embolization
US20060063732A1 (en) * 2000-03-24 2006-03-23 Jean-Marie Vogel Compositions and methods for gene therapy
US8741351B2 (en) 2000-03-24 2014-06-03 Biosphere Medical, Inc. Microspheres for active embolization
US20080220077A1 (en) * 2000-03-24 2008-09-11 Biosphere Medical, Inc. Microspheres for active embolization
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US8697137B2 (en) 2000-03-24 2014-04-15 Biosphere Medical, Inc. Methods of using microspheres for active embolization
US9040022B2 (en) 2005-05-09 2015-05-26 Biosphere Medical, S.A. Compositions and methods using microspheres and non-ionic contrast agents
US8709384B2 (en) 2005-05-09 2014-04-29 Biosphere Medical, S.A. Compositions and methods using microspheres and non-ionic contrast agents
US8226926B2 (en) 2005-05-09 2012-07-24 Biosphere Medical, S.A. Compositions and methods using microspheres and non-ionic contrast agents
US10293063B2 (en) 2005-05-09 2019-05-21 Merit Medical Systems, Inc. Compositions and methods using microspheres and non-ionic contrast agents
US20060251582A1 (en) * 2005-05-09 2006-11-09 Biosphere Medical Sa Compositions and methods using microspheres and non-ionic contrast agents
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
US10448955B2 (en) 2006-01-30 2019-10-22 Biosphere Medical, Inc. Compressible intravascular embolization particles and related methods and delivery systems
US11179159B2 (en) 2007-06-04 2021-11-23 Sequent Medical, Inc. Methods and devices for treatment of vascular defects
US9259337B2 (en) 2007-06-04 2016-02-16 Sequent Medical, Inc. Methods and devices for treatment of vascular defects
US11844528B2 (en) 2008-04-21 2023-12-19 Covidien Lp Multiple layer filamentary devices for treatment of vascular defects
US10716573B2 (en) 2008-05-01 2020-07-21 Aneuclose Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm
US10028747B2 (en) 2008-05-01 2018-07-24 Aneuclose Llc Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm
US20150150563A1 (en) * 2008-05-02 2015-06-04 Sequent Medical Inc. Filamentary devices for treatment of vascular defects
US9597087B2 (en) 2008-05-02 2017-03-21 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US20150105817A1 (en) * 2008-05-02 2015-04-16 Sequent Medical Inc. Filamentary devices for treatment of vascular defects
US10610231B2 (en) 2008-05-02 2020-04-07 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11707371B2 (en) 2008-05-13 2023-07-25 Covidien Lp Braid implant delivery systems
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
US9358140B1 (en) 2009-11-18 2016-06-07 Aneuclose Llc Stent with outer member to embolize an aneurysm
US20110319753A1 (en) * 2010-06-25 2011-12-29 Aidan Marcus Tout Systems and methods for imaging sinuses
US9198987B2 (en) * 2010-06-25 2015-12-01 Kci Licensing, Inc. Systems and methods for imaging sinuses
US20140135811A1 (en) * 2012-11-13 2014-05-15 Covidien Lp Occlusive devices
US11786253B2 (en) 2012-11-13 2023-10-17 Covidien Lp Occlusive devices
US10327781B2 (en) 2012-11-13 2019-06-25 Covidien Lp Occlusive devices
US11690628B2 (en) 2012-11-13 2023-07-04 Covidien Lp Occlusive devices
US9955976B2 (en) 2013-08-16 2018-05-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US10813645B2 (en) 2013-08-16 2020-10-27 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US10136896B2 (en) 2013-08-16 2018-11-27 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US10939914B2 (en) 2013-08-16 2021-03-09 Sequent Medical, Inc. Filamentary devices for the treatment of vascular defects
US9198670B2 (en) 2013-08-16 2015-12-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11723667B2 (en) 2013-08-16 2023-08-15 Microvention, Inc. Filamentary devices for treatment of vascular defects
US9492174B2 (en) 2013-08-16 2016-11-15 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11104772B2 (en) 2013-09-19 2021-08-31 Microvention, Inc. Polymer films
US11135167B2 (en) 2013-09-19 2021-10-05 Terumo Corporation Polymer particles
US10227463B2 (en) 2013-09-19 2019-03-12 Microvention, Inc. Polymer films
US9938367B2 (en) 2013-09-19 2018-04-10 Terumo Corporation Polymer particles
US11786630B2 (en) 2013-09-19 2023-10-17 Terumo Corporation Polymer particles
US10144793B2 (en) 2013-09-19 2018-12-04 Terumo Corporation Polymer particles
US9546236B2 (en) 2013-09-19 2017-01-17 Terumo Corporation Polymer particles
US9408916B2 (en) 2013-09-19 2016-08-09 Microvention, Inc. Polymer films
US10519264B2 (en) 2013-11-08 2019-12-31 Terumo Corporation Polymer particles
US9688788B2 (en) 2013-11-08 2017-06-27 Terumo Corporation Polymer particles
US11261274B2 (en) 2013-11-08 2022-03-01 Terumo Corporation Polymer particles
US10118980B1 (en) 2013-11-08 2018-11-06 Terumo Corporation Polymer particles
US9629635B2 (en) 2014-04-14 2017-04-25 Sequent Medical, Inc. Devices for therapeutic vascular procedures
US11678886B2 (en) 2014-04-14 2023-06-20 Microvention, Inc. Devices for therapeutic vascular procedures
US10543295B2 (en) 2015-03-26 2020-01-28 Microvention, Inc. Particles
US11857694B2 (en) 2015-03-26 2024-01-02 Microvention, Inc. Particles
US10155064B2 (en) 2015-03-26 2018-12-18 Microvention, Inc. Particles
US10792390B2 (en) 2015-03-26 2020-10-06 Microvention, Inc. Particles
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
US11116867B1 (en) 2015-04-17 2021-09-14 Teleflex Life Sciences Limited Resorbable embolization spheres
US10071181B1 (en) 2015-04-17 2018-09-11 Teleflex Innovations S.À.R.L. Resorbable embolization spheres
US10179188B1 (en) 2015-04-17 2019-01-15 Teleflex Innovations S.À.R.L. Resorbable embolization spheres
US10729805B2 (en) 2016-09-28 2020-08-04 Terumo Corporation Drug delivery polymer particles with hydrolytically degradable linkages
US11110198B2 (en) 2016-09-28 2021-09-07 Terumo Corporation Polymer particles
US11617814B2 (en) 2016-09-28 2023-04-04 Terumo Corporation Methods of treatment comprising administering polymer particles configured for intravascular delivery of pharmaceutical agents
US10201632B2 (en) 2016-09-28 2019-02-12 Terumo Corporation Polymer particles
US10632226B2 (en) 2016-09-28 2020-04-28 Terumo Corporation Polymer particles
US10328175B2 (en) 2016-09-28 2019-06-25 Terumo Corporation Polymer particles
US11759545B2 (en) 2016-09-28 2023-09-19 Terumo Corporation Polymer particles
US11559309B2 (en) 2019-03-15 2023-01-24 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11317921B2 (en) 2019-03-15 2022-05-03 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11291453B2 (en) 2019-03-15 2022-04-05 Sequent Medical, Inc. Filamentary devices having a flexible joint for treatment of vascular defects
US11685007B2 (en) 2019-11-04 2023-06-27 Covidien Lp Devices, systems, and methods for treatment of intracranial aneurysms
US11717924B2 (en) 2019-11-04 2023-08-08 Covidien Lp Devices, systems, and methods for treatment of intracranial aneurysms
US11633818B2 (en) 2019-11-04 2023-04-25 Covidien Lp Devices, systems, and methods for treatment of intracranial aneurysms
US11679458B2 (en) 2019-11-04 2023-06-20 Covidien Lp Devices, systems, and methods for treating aneurysms

Also Published As

Publication number Publication date
US10448955B2 (en) 2019-10-22
WO2007090127A3 (en) 2008-10-09
US20130190795A1 (en) 2013-07-25
EP1986707A2 (en) 2008-11-05
WO2007090127A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
US10448955B2 (en) Compressible intravascular embolization particles and related methods and delivery systems
JP6720381B2 (en) Shape memory polymer container closure device
US5456693A (en) Embolization plugs for blood vessels
US20160082144A1 (en) In-situ forming foams for embolizing or occluding a cavity
US8062282B2 (en) Methods and apparatus for temporarily occluding body openings
EP2717790B1 (en) Vascular occlusion devices
EP1824414A2 (en) Compositions, systems and methods for treatment of defects in blood vessels
JP2011502582A (en) Device and method for blocking vascular puncture
JP2005537070A (en) Embolization
JP2002522174A (en) Method and apparatus for loading a hydrogel into a cavity
JP2004520881A (en) Occlusion balloon with selective permeability and high inflation
JP2007512116A (en) Hemostatic pressure embolus
JPH10127754A (en) Occlusion material composed of collagen
CN107096064B (en) Preparation method of super-porous composite hemostatic material capable of expanding rapidly
US20080086156A1 (en) Methods and devices for using drug-eluting embolization
JP4225960B2 (en) Flexible tissue closure system
CN115584050A (en) Gelatin sponge, preparation method thereof and embolism material prepared from gelatin sponge
CN115089255A (en) Biodegradable medical spring ring and application thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: RJ MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SURGICA CORPORATION;REEL/FRAME:021526/0845

Effective date: 20080627

Owner name: BIOSPHERE MEDICAL, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RJ MEDICAL, INC.;REEL/FRAME:021526/0848

Effective date: 20080612

Owner name: SURGICA CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATSON, LOUIS R.;MCNAMARA, GERALD P.;BRANDOM, DONALD K.;REEL/FRAME:021526/0829;SIGNING DATES FROM 20080618 TO 20080812

AS Assignment

Owner name: SURGICA CORPORATION, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 01/30/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0829. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF U.S. SERIAL NO. 11/669,119 TO ASSIGNEE SURGICA CORPORATION NUNC PRO TUNC EFFECTIVE AS OF 01/30/2007.;ASSIGNORS:MATSON, LOUIS R.;MCNAMARA, GERALD P.;BRANDOM, DONALD K.;REEL/FRAME:021548/0362;SIGNING DATES FROM 20080618 TO 20080812

Owner name: RJ MEDICAL, INC., CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 12/19/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0845. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF U.S. SERIAL NO. 11/669,119 TO ASSIGNEE RJ MEDICAL, INC. EFFECTIVE AS OF 12/19/2007.;ASSIGNOR:SURGICA CORPORATION;REEL/FRAME:021554/0260

Effective date: 20080627

Owner name: SURGICA CORPORATION, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 01/30/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0829;ASSIGNORS:MATSON, LOUIS R.;MCNAMARA, GERALD P.;BRANDOM, DONALD K.;REEL/FRAME:021548/0362;SIGNING DATES FROM 20080618 TO 20080812

Owner name: RJ MEDICAL, INC., CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET NATURE OF CONVEYANCE FROM ASSIGNMENT TO NUNC PRO TUNC ASSIGNMENT; EFFECTIVE DATE 12/19/2007 PREVIOUSLY RECORDED ON REEL 021526 FRAME 0845;ASSIGNOR:SURGICA CORPORATION;REEL/FRAME:021554/0260

Effective date: 20080627

AS Assignment

Owner name: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINIS

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:BIOSPHERE MEDICAL, INC.;REEL/FRAME:029698/0237

Effective date: 20121219

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION